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Abstract   
Key augmented processes in atherosclerosis have been identified, whereas less is known 
about downregulated pathways. Here we applied a systems biology approach to examine 
suppressed molecular signatures, with hypothesis that they may provide insight into 
mechanisms contributing to plaque stability.  
‘Muscle contraction’, ‘muscle development’ and ‘actin cytoskeleton’ were the most 
downregulated pathways (FDR=6.99e-21, 1.66e-6, 2.54e-10 respectively) in microarrays 
from human carotid plaques (n=177) vs. healthy arteries (n=15). In addition to typical SMC 
markers, these pathways also encompassed cytoskeleton-related genes previously not 
associated with atherosclerosis. SYNPO2, SYNM, LMOD1, PDLIM7, and PLN expression 
positively correlated to typical SMC markers in plaques (Pearson r>0.6, p<0.0001) and in rat 
intimal hyperplasia (r>0.8, p<0.0001). By immunohistochemistry, the proteins were 
expressed in SMCs in normal vessels, but largely absent in human plaques and intimal 
hyperplasia. Subcellularly, most proteins localised to the cytoskeleton in cultured SMCs and 
were regulated by active enhancer histone modification H3K27ac by ChIP-seq. Functionally, 
the genes were downregulated by PDGFB and IFNg, exposure to laminar shear stress and 
oxLDL loading. Genetic variants in PDLIM7, PLN and SYNPO2 loci associated with 
progression of carotid intima-media thickness in high-risk subjects without symptoms of 
cardiovascular disease (n=3378). By eQTL, rs11746443 also associated with PDLIM7 
expression in plaques. Mechanistically, silencing of PDLIM7 in vitro lead to downregulation of 
SMC markers and disruption of the actin cytoskeleton, decreased cell spreading and 
increased proliferation.   
We identified a panel of genes that reflect the altered phenotype of SMCs in vascular 
disease and could be early sensitive markers of SMC dedifferentiation. 
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Abbreviations 
AF- amaurosis fugax 
AHA- American Heart Association 
AS-asymptomatic 
BiKE- Biobank of Karolinska Endarterectomies 
CEA- carotid endarterectomy 
CP- carotid plaque 
CHip- chromatin immunoprecipitation 
CNN- calponin 
cIMT- carotid intima-media thickness 
ECM- extracellular matrix 
LMOD1-leiomodin 1 
GEO- Gene Expression Omnibus 
IHC- immunohistochemistry 
IFL- immunofluorescence 
MS- minor stroke 
MYOCD- myocardin 
MYH11- myosin heavy chain 11 
NA- normal artery 
NCA- normal carotid artery 
PCNA- proliferating cell nuclear antigen  
PDGF- platelet derived growth factor 
PLN- phospholamban 
PDLIM7- PDZ and LIM domain containing 7 
RNAseq- RNA sequencing 
qPCR- quantitative polymerase chain reaction 
FDR- false discovery rate 
S- symptomatic 
SMC- smooth muscle cell 
SMA- smooth muscle actin 
SYNM- synemin 
SYNPO2- synaptopodin 2 
TIA- transitory ischemic attack 
TAGLN- transgelin 
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Introduction 
Unstable atherosclerosis in the carotid bifurcation is a common cause of stroke, and 
guidelines recommend treatment with stroke-preventive carotid endarterectomy (CEA) in 
patients with signs of cerebral embolism1. Stable, asymptomatic (AS) carotid lesions are 
generally rich in extracellular matrix (ECM) and smooth muscle cells (SMCs), whereas 
unstable (symptomatic, S) plaques contain abundant inflammatory cells and a thin fibrous 
cap prone to rupture2. Inflammation, cytokines, mitogens, ECM degradation and altered cell-
matrix interactions have been associated with intraplaque processes in atherogenesis which 
promote activation of contractile SMCs in the media into a secretory and replicating 
phenotype that engage in intimal remodeling and formation of the fibrous cap.  
Contractile SMCs are distinguished from other cell types by expression of a unique repertoire 
of markers including Smooth Muscle Actin (SMA, ACTA2), Calponin (CNN1), Transgelin 
(TAGLN), Myocardin (MYOCD) and Myosin Heavy Chain 11 (MYH11), mostly associated 
with the acto-myosin cytoskeleton. These genes are downregulated in activated SMCs and 
may be undetectable using traditional immunohistochemical staining methods3, 4. However, it 
is unclear whether altered expression of these genes takes place concomitantly or 
successively during phenotypic modulation. This problem is notable in atherosclerotic lesions 
where SMA positive (SMA+) cells define several distinct regions and can be found in the 
necrotic core and the fibrous cap (Figure 1A). Recently, SMC transdifferentiation into CD68+ 
macrophage-like cells has been demonstrated in atherosclerosis5, 6 which further emphasizes 
the complexity in characterizing SMC phenotypes in vascular disease. Apart from 
atherogenesis, activation of SMCs also dominates in healing reactions aimed to repair the 
vessel after injury, healing of ruptured atheromas7, restenosis after arterial interventions8 and 
in the failure of vein grafts and dialysis fistulas9.  
Understanding the molecular and cellular processes that convert asymptomatic plaques into 
symptomatic ones may facilitate the development of preventive pharmacotherapy with 
unprecedented impact on cardiovascular mortality and morbidity. For this purpose, intensive 
efforts have been dedicated to the identification of suitable targets through analysis of 
augmented pathways and molecules in vulnerable lesions10, 11. In contrast, less is known 
about pathways that are inhibited in atherogenesis and in the process of plaque instability. 
Since identification of such inherent functional changes within the vessel wall may give clues 
to therapies that can sustain arterial resistance to atherogenic stimuli or improve stability of 
established complex lesions, studies of downregulated genes and suppressed pathways may 
be equally important12. Identifications of ultimately translatable target molecules are bound to 
be more successful when generated directly from human disease, followed by clinical and 
experimental exploration. 
Recently we performed a comprehensive transcriptomic analysis of late-stage human carotid 
atherosclerosis based on defined clinical patient phenotypes13. Our findings confirmed a 
central role for lipid accumulation, inflammation and proteases in plaque instability, and 
highlighted haemoglobin metabolism and bone resorption as important enriched pathways in 
plaques. Here, we instead analysed downregulated molecular signatures in carotid plaques 
by applying an integrative framework based on collaboration of three large human biobanks: 
initial discoveries were made using material from the Biobank of Karolinska 
Endarterectomies (BiKE, n=177 plaques from end-stage atherosclerosis patients and n=15 
macroscopically healthy, normal arteries); data was further validated using atheroprogression 
samples from the SOKRATES biobank (n=28 patients tissues); and genetic analyses were 
performed in the IMPROVE cohort (n=3378 high-risk patients without symptoms or signs of 
cardiovascular disease). We found that SMC-related functional categories were the most 
significantly affected in plaques and identified a set of downregulated SMC-related genes 
previously poorly studied in vascular disease. Temporal changes in the expression of these 
genes were followed in the rat carotid injury model and in primary SMCs in vitro in 
comparison with typical SMC markers. Genetic association with progression of carotid 
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intima-media thickness (cIMT) as a surrogate marker of atherosclerosis, was investigated in 
the large cohort of high-risk subjects and mechanistic studies were performed for one of 
these genes in vitro. We report a panel of novel SMC markers that are suppressed in 
vascular disease in humans and reflect the altered phenotype of SMCs during vascular 
remodelling.  
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Material and Methods 
Material and Metods are available in the online-only Data Supplement.  
Results 
Genes and pathways associated with SMCs are repressed in atherosclerosis 
Pathways associated with ‘muscle contraction’, ‘muscle development’ and ‘actin cytoskeleton’ 
were the most significantly downregulated in microarrays comparing late-stage human 
carotid plaques (CP) vs. normal arteries (NA) as well as in plaques extracted from 
symptomatic vs. asymptomatic patients (e.g. in CP vs. NA comparison FDR=6.99e-21, 
1.66e-6 and 2.54e-10 respectively, Supplementary Table I). Genes clustered in these 
categories were the typical markers of SMCs and acto-myosin cytoskeleton (Supplementary 
Fig IA). Among the most significantly downregulated genes appeared several whose function 
in SMCs was previously unexplored in the context of atherosclerosis: LMOD1 (Leiomodin 1), 
SYNPO2 (Synaptopodin 2), PLN (Phospholamban), PDLIM7 (PDZ and LIM domain 
containing 7) and SYNM (Synemin). By constructing functional networks from their extended 
protein-protein interactions and expression profiles across tissues 14-16, we noted that these 
genes were co-expressed with actin and microtubule markers (Figure 1B) and some of them 
also co-interacted with the cytoskeleton based on available public data (i.e. PDLIM7, SYNM, 
LMOD1 and SYNPO2; Supplementary Figure IB). Strong downregulation of these transcripts 
was found in two non-overlapping microarray datasets comparing carotid plaques to normal 
arteries (n=127 CP vs. n=10 NA and n=50 CP vs. n=5 NA, p<0.0001 for most transcripts) 
and downregulation was also noted in plaques from symptomatic vs. asymptomatic patients 
(n=87 S vs 40 AS, p<0.01) (Figure 1C, full list in Supplementary Table II). In support of these 
findings, their protein levels were also lower in plaques from S vs. AS patients, as 
determined by mass spectrometry (n=10 S vs 10 AS, Supplementary Figure II). Additionaly, 
a trend towards downregulation of these genes was observed in publicly available microarray 
datasets comparing n=12 human carotid plaques vs. n=9 normal arteries 10 and n=32 carotid 
plaques vs. matched adjacent tissue (GSE43292). Strong positive correlations were seen 
between mRNA expression of LMOD1, SYNPO2, PLN, PDLIM7 and SYNM in carotid 
plaques and typical SMC markers such as ACTA2, MYH11, CNN1, MYOCD (Pearson r>0.6, 
p<0.0001, representative examples in Figure 1D, full data in Supplementary Table III). 
Similarly, strong correlations between corresponding protein levels, as determined by mass 
spectrometry, were also demonstrated (Pearson r>0.8, p<0.0001, Supplementary Table III). 
To further investigate the association of the selected genes with SMCs, we analyzed a 
publicly available microarray dataset (GSE23303) comparing microdissected SMC-rich 
subintimal regions of carotid plaques with macrophage-rich regions from the necrotic core. 
We found that mRNA levels of these genes were strongly downregulated in macrophage-rich 
compared with SMC-rich regions, while no significant difference was seen in this comparison 
for ACTA2 (Supplementary Table II).  
To experimentally corroborate our findings from human plaques, we analyzed the expression 
of the selected genes in an inducible plaque rupture model on ApoE background, where mice 
present atherothombotic events and morphological signs of plaque instability 17. Expression 
of all 5 genes of interest was strongly downregulated in ligated vs. non-ligated arteries (i.e. 
mRNA fold change= -114, p<0.0001 for Synpo2; fold change= -45, p<0.0001 for Lmod1), 
and marginally also in comparison between ruptured vs. stable plaques, thus replicating 
results from the human datasets (Supplementary Table IV).  
Collectively, these results demonstrated that we have identified a set of previously poorly 
characterised genes through transcriptomic profiling of late-stage human atherosclerosis, 
likely associated with loss of contractile SMC features in the disease.  
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LMOD1, SYNPO2, PDLIM7, SYNM and PLN are expressed by SMCs  
The localisation of selected genes and proteins in normal human vessels and carotid plaques 
was performed by in situ RNA hybridization and immunohistochemistry and compared with 
typical SMC markers such as MYH11, CNN1 and SMA, including proliferating cell nuclear 
antigen (PCNA) as a marker of cell proliferation. By immunohistochemistry, MYH11, 
considered to be an early marker of phenotypic changes in SMCs3, was only detected in 
PCNA- SMCs in normal carotid artery media but was absent in late-stage plaques, while 
CNN1 was detectable in the normal artery as well as in subintimal SMA+/PCNA- cells and in 
SMA+ cells in the fibrous cap of carotid plaques (Figure 2A). By co-immunostaining, SMA, 
LMOD1, SYNPO2, PDLIM7, SYNM and PLN were all abundantly expressed in SMCs in 
normal arteries (carotid artery stainings shown in Figure 2B). The stainings appeared mostly 
cytosolic, except in the case of PLN, which exhibited nuclear staining. In late-stage plaques, 
PDLIM7 was present in subintimal SMCs and weak expression was also detected in stellate-
shaped SMA+ cells in the fibrous cap. SYNM showed a similar staining pattern in subintimal 
SMCs but was absent from the fibrous cap. SYNPO2, LMOD1 and PLN were not detectable 
in these plaques by immunohistochemistry. RNA transcripts of MYH11, CNN1, ACTA2 and 
selected genes were all detectable in the normal artery media and to a lesser extent also in 
cells with elongated nuclei in the fibrous cap (except PLN, Supplementary Figure III).  
We further investigated the expression of these genes during atheroprogression, using 
human aortic lesions from different stages of disease graded according to the modified 
American Heart Association criteria18, ranging from adaptive intimal thickening and xantomas 
(stages I and II), via pathological intimal thickening (stage III) to early and thin-cap 
fibroatheromas (stages IV and V). In these lesions, SMA and CNN1 were detectable in 
SMCs from early stages to advanced lesions, while MYH11 as expected, was absent from 
PCNA+ SMCs already at stage I (Supplementary Figure IV). LMOD1 and SYNPO2 were 
mostly absent already from stage I, PLN was not detectable from stage III, whereas SYNM 
and PDLIM7 were present in subintimal SMCs but sparsely in cells that build the fibrous cap 
from stage III. Interestingly, in human intimal hyperplasia, we observed the reappearance of 
both typical SMC markers and the selected genes in SMA+/PCNA- areas (Figure 2). 
Abundant signal was observed for CNN1 as well as for PDLIM7 and SYNM, while LMOD1, 
SYNPO2 and PLN were sparsely present. Our results confirm that these genes localise to 
quiescent SMCs in normal artery media and undergo various degrees of downregulation at 
both transcript and protein levels in activated SMA+ cells of lesions, with reappearance in 
mature intimal hyperplasia. Of note, these proteins were also detected in SMA+ cells in 
several other smooth muscle-rich tissues (Supplementary Figure V).  
Lmod1, Synpo2, Pdlim7, Synm and Pln are downregulated early in reponse to 
experimental vascular injury but reappear in mature neointima  
Time-dependent alterations in expression of SMC markers were examined by transcriptomic 
analysis from rat carotid arteries after balloon injury (Figure 3). Typical SMC genes along 
with Lmod1, Synpo2, Pdlim7, Synm and Pln showed similar gene expression profiles with 
gradual downregulation in the early phases after injury, but upregulation after 2-12 weeks in 
the mature neointima. Expression correlations of Lmod1, Synpo2, Pln, Pdlim7 and Synm with 
typical SMC markers in this model were strongly positive (mostly Pearson r>0.8, p<0.0001, 
Figure 3C, Supplementary Table III) and negative with cytokines such as Pdgfb, Igf1 and 
Tgfb1 (Figure 3C). By IHC, we observed loss of CNN1 from PCNA+ SMC layers closer to the 
lumen, while the staining was still present in deeper medial layers at day 5 and again 
abundant in the mature intima with reduced PCNA staining 12 weeks after injury (Figure 4A). 
Staining for LMOD1, SYNPO2, PDLIM7, SYNM and PLN was absent at day 5 with gradual 
reappearance in medial SMCs in tissues with pronounced intimal hyperplasia 12 weeks after 
injury (Figure 4B). No similar changes in gene expression patterns were found in 
contralateral uninjured arteries (Supplementary Figure VI). These analyses indicated that 
downregulation of Lmod1, Synpo2, Pln, Pdlim7 and Synm might functionally relate to SMC 
activation in response to injury.   
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LMOD1, SYNPO2, SYNM, PDLIM7 and PLN localise mostly to actin-cytoskeleton in 
SMCs and relate to phenotypic changes in vitro  
To address the expression of the selected genes during the process of SMC phenotypic 
modulation, rat aortic SMCs were isolated by collagenase digestion, seeded on fibronectin 
and cultured in serum-free medium or medium supplemented with PDGFBB for 7 days19. 
Directly upon isolation (day 0), almost 90% of the cells were SMA+ by flow cytometry, 
although lower SMA levels in a subgroup of cells were detectable (Figure 5A). After 7 days, 
95% of the population cultured in serum-free medium uniformly expressed higher levels of 
SMA, while cells stimulated with PDGFBB showed presence of two subpopulations of which 
one expressed lower signal for SMA (totally 77% SMA+ cells, Figure 5A, detailed analysis 
shown in Supplementary Figure VII). By qPCR, mRNA levels of Acta2, Myocd and Myh11 as 
well as Lmod1, Synpo2, Pdlim7, Synm and Pln strongly decreased from day 1 to day 3 in 
culture, but on day 5 and 7 the expression of most of these genes (except Synm) gradually 
increased. At each reference time-point, cells cultured in the presence of PDGFBB showed 
downregulation of the target genes compared to cells in serum-free medium (Figure 5B). By 
RNA-sequencing, downregulation of LMOD1, SYNPO2, PDLIM7, SYNM and PLN was also 
observed in low-passage human SMCs cultured in serum-supplemented (de-differentiation 
condition) vs. serum-free medium (Supplementary Table V).  
By ChIP-sequencing, we observed that all these genes were under the regulation of active 
enhancer histone modification H3K27ac (Supplementary Table VI). Prediction of putative 
binding motifs in genomic sequences using MSigDB software searching a span of 2000 
basepairs around the transcription start site, we found 3 CArG motifs present upstream of 
human PDLIM7 (at positions +650, +654, +667) and one SRF binding site in the PLN gene, 
but no such motifs were found in either SYNPO2, LMOD1 or SYNM in this analysis. Another 
prediction program MotifMap, searching a wider region within 8000 basepairs around the 
transcription start, suggested regulation by several other transcription factors previously 
associated with SMCs or control of cell proliferation. Here, TEF1 and MAFA were predicted 
to regulate LMOD1; AP1 and SRF to regulate PDLIM7; TEF1 and SRF to regulate PLN; and 
CTCF and NEUROD to control SYNPO2 (full list in Supplementary Table VII).  
Subcellular localization of SMC markers was also assessed in low-passage human SMCs 
(Figure 5C, additional images shown in Supplementary Figure VIII). CNN1, PDLIM7 and 
SYNPO2 were localized to the actin cytoskeleton by overlap with phalloidin staining; SYNM 
localized to cellular filopodia and to the cortical cytoskeleton; PLN exhibited nuclear staining 
while MYH11 and LMOD1 could not be detected in these cells. Taken together, our data 
confirm that SMCs maintain phenotypic plasticity in vitro and show that the expression 
changes and cytoskeletal localization of the selected genes strongly correlate with those of 
typical SMC markers in vitro, as initially observed in situ.  
Downregulation of LMOD1, SYNPO2, SYNM, PDLIM7 and PLN in response to 
inflammatory-, hemodynamic- and lipid stimuli 
Next, we explored processes relevant in the environment of an atherosclerotic lesion that 
may influence expression of the genes identified in our study. The expression of standard 
SMC markers as well as LMOD1, SYNPO2, SYNM, PDLIM7 and PLN was rapidly 
downregulated in human SMCs in vitro by stimulation with IFNg (Figure 6A). Downregulation 
of all genes was observed within 24h of IFNg treatment, whereas expression of PLN, 
PDLIM7, SYNM and SYNPO2 was suppressed already after 2h. These genes were also 
downregulated in human SMCs after 48-72hrs stimulation with oxLDL (in particular SYNPO2, 
LMOD1 and PLN, Figure 6B), which was validated by analyzing a public microarray dataset 
comparing cholesterol-loaded primary mouse aortic SMCs with baseline controls (GSE47744, 
Supplementary Figure IX)20. In this model, the typical SMC markers ACTA2 and CNN1 were 
also downregulated, whereas the macrophage marker CD68 was upregulated. Finally, we 
analyzed expression of these genes in an in vitro model of SMC exposure to laminar shear 
stress, mimicking the exposure of the injured vessel surface to the hemodynamic forces of 
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the flowing blood21. In microarrays comparing shear stress vs. static conditions, we have 
previously observed apoptosis as an enriched pathway through activation of CASP3 (dataset 
accession nr GSE19909) and all genes (as well as other typical SMC markers) were also 
found to be downregulated in this model (Figure 6C).  
Collectively, our results demonstrate that downregulation of LMOD1, SYNPO2, SYNM, 
PDLIM7 and PLN along with standard SMC markers, functionally relates to clinical symptoms 
of plaque instability, vascular injury, as well as to key molecular processes in atherosclerosis 
such as apoptosis, shear stress, inflammatory stimuli and lipid-uptake. 
Polymorphisms in PDLIM7, SYNPO2 and PLN associate with surrogate markers of 
atherosclerosis  
In order to investigate the involvement of LMOD1, SYNPO2, PDLIM7, SYNM and PLN in 
early processes shown to be predictive of carotid and coronary artery disease in humans, we 
examined the association of genetic variants in these loci with severity and rate of cIMT 
progression. Several variants in the PDLIM7, SYNPO2 and PLN genomic regions were found 
to be associated with cIMT phenotypes in a large cohort of high-risk subjects (n=3378, 
IMPROVE)22 after adjustment for age, gender and population stratification (Supplementary 
Table VIII). Variants rs11746443 and rs35716097 (PDLIM7) associated with the maximum 
thickness of the common carotid artery (p=0.002) and the fastest cIMT progression 
(p=0.0009, p=0.002, respectively), and variants rs67456868 (PLN) and rs4833611 (SYNPO2) 
were associated with the maximum common carotid artery thickness (p=0.00004, p=0.0007, 
respectively). Full functional information obtained from Haploreg for these variants is 
presented in Supplementary Tables IX and X. The SYNPO2 variant rs4833611 was located 
in the intronic region of the USP53 gene and by eQTL analyses marginally linked to SYNPO2 
(p=0.09) and USP53 (p=0.02) gene expression in plaques. Of particular interest, PDLIM7 
variant rs35716097 was predicted to constitute a putative binding site for HNF4A 
transcription factor. The other PDLIM7 variant rs11746443 was localised in the genomic 
region of RGS14 and predicted to constitute the binding site for the HEY1 transcription factor, 
while its proxy (rs4075958, Rsquared=0.927, Dprime=0.963) was mapped within the putative 
binding site for the ETS1 transcription factor. By eQTL analysis in plaques, rs4075958 was 
found to be significantly associated with the expression of both PDLIM7 and RGS14 
(p=0.007 and p=0.0002 respectively, Figures 7A and 7B) and the expression levels of both 
genes were strongly correlated (Pearson r=0.61, p<0.0001) (Figure 7C). PDLIM7 and 
RGS14 also appeared to be linked in a protein interaction network via actin cytoskeleton and 
markers of differentiated SMCs, SMTN and CNN2 (Figure 7D). Altogether, our results 
underline the possiblity that genetic variants associated with PDLIM7 may be causal to 
altered intima-media phenotypes and predisposition to atherosclerosis.  
Silencing of PDLIM7 leads to downregulation of other SMC markers and increased 
SMC proliferation  
Of the five genes that were identified, PDLIM7 emerged as one of the key drivers of 
pathological processes in atherosclerosis13. Since PDLIM7 was causally implicated in 
atherogenesis at the genetic level, localised to SMC actin cytoskeleton and in addition, 
interconnected with other cytoskeletal proteins, we decided to mechanistically investigate its 
role in SMCs. Silencing PDLIM7 expression in human carotid SMCs in vitro, resulted in 
downregulation of other SMC markers (ACTA2 by approximately 30%, MYH11 by 50%, 
LMOD1 by 30%, and particularly SYNPO2 by 70% and PLN by 50% on the mRNA level). 
Cell adhesion and spreading on fibronectin were defective compared with controls, and 
proliferation was significantly increased in these cells as evaluated by BrdU incorporation 
(Figure 8, Supplementary Figure X). These findings add mechanistic support that PDLIM7 is 
a critical structural molecule in the regulation of SMC phenotype. 
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Discussion 
A large biobank of carotid endarterectomies obtained from patients undergoing surgery for 
symptomatic or asymptomatic carotid stenosis was used to identify suppressed processes in 
atherosclerosis. We found molecular pathways related to SMC function and phenotype but 
also a panel of genes (SYNPO2, SYNM, LMOD1, PDLIM7, PLN) previously not associated 
with vascular disease, not only to be the most repressed in end-stage atherosclerosis but 
also in relation to clinical symptoms of plaque instability, both on the transcriptomic and 
proteomic level. We hypothesized that some of these genes may show early expression 
variations and demarcate the initiation of SMCs phenotypic switching. Most of these genes 
were linked to the SMC cytoskeleton, downregulated during neointima formation after rat 
carotid balloon injury, and polymorphisms in PDLIM7, PLN and SYNPO2 genomic regions 
were associated with cIMT phenotypes in high-risk subjects. In addition, expression of these 
genes was sensitive to predominant processes in the atherosclerotic lesion such as 
apoptosis, inflammation, hemodynamic stress, and lipid exposure. We propose that these 
SMC genes may improve definition of the phenotypic state of these cells in vascular disease 
and may be further explored related to the capacity of SMCs to contribute to plaque 
stabilization.  
Previously, transition of SMCs from a contractile and quiescent phenotype into synthetic, 
matrix-producing and replicating cells has been widely accepted as a central feature in early 
atherogenesis and an essential part of lesion stability and repair. This process, where the 
typical contractile features of SMCs are lost, represents an example of disturbed vessel wall 
homeostasis in disease progression. However, it has become evident that these conclusions 
oversimplify the complexity of SMC function in vascular disease and that these phenotypes 
probably represent the extremes of a spectrum of intermediate phenotypes that may to 
various extents coexist in the vessel wall, as dictated by exposure to environmental cues 
affecting gene expression patterns23. Recent studies have presented strong evidence that 
SMCs and macrophages can activate the same genes by demonstrating that 50% of foam 
cells within advanced human coronary artery lesions express the SMC marker SMA besides 
the macrophage marker CD68, while lineage tracing in mice confirmed that up to 80% of the 
lesion cells (including mesenchymal stem cells and macrophage-like cells) are SMC-derived5, 
6. Here, we demonstrated that a number of SMC markers remain repressed on the protein 
level in stellate-shaped SMA+ cells of the fibrous cap, whereas expression was still 
detectable on the transcript level in situ, as previously reported by others24. Together, these 
observations highlight the problem of correct SMC identification with respect to our 
understanding of human disease. Other studies seeking to establish the earliest 
determinants of SMC phenotypic switch have shown that e.g. mitochondrial fragmentation 
represents an early mark of SMC activation25. Currently, changes in histone modifications, 
novel SMC-enriched transcription factors such as TCF21 and TET226-29 and epigenetic 
regulation of SMC phenotype by noncoding RNAs30 are also being intensively investigated. 
Nevertheless, our study highlights that we have not yet fully explored the transcriptomic 
landscape in relation to the plethora of SMC phenotypes and adds to elucidation of molecular 
signatures that characterize their plasticity.  
Here, we confirmed that muscle-contraction, muscle-development and acto-myosin 
cytoskeleton were some of the most repressed categories in atherosclerotic tissue, including 
typical markers of SMCs as well as a number of genes previously poorly characterised in the 
context of SMC function. Synemin (SYNM) is an intermediate filament protein whose 
knockdown in saphenous vein SMCs in vitro leads to increased collagen production, 
downregulation of typical SMC markers and disassembly of actin fibers31. Phospholamban 
(PLN), a regulator of Ca2+ homeostasis, was previously immunolocalized to the nuclear 
envelope and sarcoplasmic reticulum of cardiac SMCs32. In a recent study, PLN mutations 
were linked to dilated cardiomyopathy, ventricular arrhythmias and interstitial fibrosis33. 
Nanda V et al.34 described Leiomodin 1 (LMOD1) as a new SMC-restricted, myofilament-
related, SRF/MYOCD target gene enriched in SMCs in embryonic and adult mouse tissues. 
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Earlier, LMOD1 was predicted to belong to a ‘gene battery’ involved in SMC differentiation by 
a bioinformatics screen for regulators of conserved functional gene modules in mammals35. 
Interestingly, Synaptopodin (SYNPO) and PDLIM proteins have been discovered as neuronal 
components and also investigated as adaptor molecules orchestrating actin-cytoskeletal 
organization in foot processes of podocytes36-39, but sparsely linked to SMCs40-43. Apart from 
these few publications, limited information exists about these genes in the literature up to 
date, and to the best of our knowledge, this study is the first to systematically examine their 
implication in human atherosclerosis and vascular remodelling.  
SMCs are currently considered to be the main cell type responsible for intimal repair after 
balloon injury in the rat carotid artery, although cells of mesenchymal origin may also 
contribute 44. In this model, intimal hyperplasia develops in three major stages45, 46 with initial 
SMC activation, replication and beginning of migration to the luminal surface during the first 
two days after injury. Between days two and five, SMCs colonise the intimal surface following 
activity related to chemoattractants and ECM degradation. In the next few weeks, the 
number of SMCs in the neointima continues to increase, but from one month after injury, 
SMC proliferation ceases, the cells become quiescent and regain ultrastructural features 
typical for the contractile state46. Our results show that expression profiles for both typical 
SMC markers and for Synm, Pln, Lmod1, Synpo2 and Pdlim7 reflect these stages by gradual 
downregulation until five days after injury, followed by subsequent upregulation later as 
SMCs become quiescent and regain contractile features. In a similar fashion, 
immunohistochemical staining for typical SMC markers as well as for SYNM, PLN, LMOD1, 
SYNPO2, and PDLIM7 was detected in human intimal hyperplasia, especially in large PCNA- 
areas. Based on these results we hypothesize that SYNM, PLN, LMOD1, SYNPO2, and 
PDLIM7 functionally relate to the phenotypic state of SMCs.   
Freshly isolated rat aortic SMCs seeded on fibronectin and cultured under serum-free 
conditions have previously been used to study the subcellular properties related to SMC 
phenotypic modulation in vitro. Under these conditions, interactions between fibronectin, 
integrin α5β1 and FAK-dependent intracellular signalling promote cell cycle entry and 
dedifferentiation into a synthetic state, accompanied by structural reorganisation and loss of 
myofilaments19, 47, 48. Here, we observed that Synm, Pln, Lmod1, Synpo2 and Pdlim7 (as well 
as Acta2, Myocd, Myh11) were indeed downregulated in primary rat SMCs during the first 
days of culture on fibronectin, but reexpressed from about 5 days of culture, suggesting that 
SMCs retain their inherent plasticity in vitro. Several of the examined genes were localised to 
the actin cytoskeleton in human SMCs implying that they may be involved in reorganisation 
of cytoskeletal structures. Interestingly, while plasticity of SMCs and re-expression of target 
genes and proteins was apparent in human and rat intimal hyperplasia, expression of the 
proteins remained repressed in stellate-shaped SMA+ cells of the fibrous cap in carotid 
plaques. As discussed, this may either be due to a heterogeneous population of cells 
expressing SMA5, 6 or repression of these genes in SMCs by disease specific factors such as 
inflammatory-, apoptotic-, or lipid mediators.   
Therefore, in order to explore whether dominant processes in the atherosclerotic 
environment may influence the genes of interest in our study, we investigated the expression 
of SYNM, PLN, PDLIM7, LMOD1 and SYNPO2 as well as other typical SMC markers in 
SMCs exposed to disease-associated stimuli in vitro. To summarize, while we have not yet 
fully dissected which specific, or combination of, stimuli may repress expression of SYNM, 
PLN, PDLIM7, LMOD1 and SYNPO2 in atherosclerosis, we showed that they were 
downregulated in response to shear stress (and apoptosis), inflammatory stimuli and 
cholesterol-uptake. In support of these observations, exposure to lipids has previously been 
associated with dramatic effects on SMC phenotype and transdifferation into CD68+ 
macrophage-like foam cells, as also demonstrated in our study 20.  
Intima–media thickness of extracranial carotid arteries, measured by ultrasound is a 
commonly accepted non-invasive marker of subclinical atherosclerosis. Several studies have 
established that cIMT changes over time are associated with vascular risk factors22 and 
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prediction of vascular events both in subjects with plaques at baseline and in those without. 
Here, genetic variants in PDLIM7, SYNPO2 and PLN showed association with cIMT 
measurements, suggesting that these genes could have a causal role in carotid disease. Of 
note, SYNPO2 variants were located in the intron of USP53 gene and marginally linked to 
expression in BiKE atherosclerotic plaques. USP53 (Ubiquitin Specific Peptidase 53) is a 
poorly studied protein, highly expressed in the heart muscle and found to be genetically 
associated with the Cantu syndrome, a rare condition characterized clinically by 
hypertrichosis, cardiomegaly and bone abnormalities49. Of particular interest, PDLIM7 SNPs 
linked to fastest-IMTmax-progression were shown to influence expression of PDLIM7 in 
plaques and predicted to constitute binding sites for transcription factors previously 
implicated in cardiovascular development, SMC migration, and SMC proliferation in response 
to cytokine stimulation50, 51. One of these SNPs was positioned in the intronic region of the 
RGS14 gene, and interestingly, the expression of RGS14 also strongly correlated with the 
expression of PDLIM7 in plaques. RGS14 has been shown to act as a positive modulator of 
microtubule polymerisation and spindle organization during cell division by integrating G 
protein and MAPK signaling pathways52, 53. It inhibits PDGF-stimulated ERK1/ERK2 
phosphorylation and may indirectly interact with PDLIM7 via the actin-cytoskeleton.  
The importance of PDLIM7 for SMC phenotype was confirmed by silencing experiments that 
resulted in perturbed cytoskeletal structure, adhesion and spreading as well as SMC 
proliferation. Previous studies in other cell types have shown similar effects of PDLIM7 
knock-down on proliferation (i.e. periodontal ligaments54) and studies of other PDLIM family 
members have shown that they can directly interact with actin-cytoskeleton proteins such as 
α-actinin-4 to stabilise actin fibres39. Similarly, missense mutations of ACTA2 in humans are 
associated with diminished gene expression, defective actin-filaments and actin-based 
spreading in SMCs, and formation of occlusive lesions due to increased SMC proliferation 
and intimal hyperplasia55, 56. Overall, our findings suggest a critical structural and mechanistic 
role for PDLIM7 in SMCs, with possible genetic influence on disease development.   
Because the BiKE cohort comprises only late-stage lesions and cannot provide information 
about gene expression variations during atheroprogression, expression data was 
complemented with immunohistochemistry on aortic lesions collected from different stages of 
atherosclerotic disease. Of note, PCNA that was used as a proliferation marker in the 
immunohistochemical analysis, has been reported to overestimate the number of replicating 
cells. Consensus is lacking regarding the selection of appropriate control tissues, and in the 
BiKE study, control vessels contained outer media that is not included in the endarterectomy 
samples. Furthermore, the discovery approach in our study was based on microarrays and 
the complexity of microarray data was reduced by pathway analyses and construction of 
functional networks where genes were clustered based on biological functions or protein 
interactions. While this method is limited to semantic mining of existing knowledge from 
published literature and databases, it still permits for discovery of poorly explored genes in a 
certain context.  
In conclusion, using a systems biology approach by integrating transcriptomic, in situ, in vivo, 
in vitro and genetic studies we were able to overcome these limitations and discover several 
novel candidates that demarcate early phenotypic modulation of SMCs in vascular disease. 
In perspective, the full knowledge of key expression signatures is likely to help us derive a 
better definition of various SMC phenotypes that coexist in the vessel wall, and provide 
targets for prevention and therapy in vascular disease.  
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
Significance  
A large biobank of carotid endarterectomies obtained from patients undergoing surgery for 
symptomatic or asymptomatic carotid stenosis was utilized to uncover genes and 
mechanisms repressed in atherosclerosis. Results demonstrated enrichment of molecular 
pathways related to smooth muscle cell (SMC) function and identified a panel of 
downregulated SMC genes previously not associated with vascular disease. These genes 
(SYNPO2, SYNM, LMOD1, PDLIM7 and PLN) were related to the SMC cytoskeleton, they 
were transiently downregulated during neointima formation after rat carotid balloon injury, 
and polymorphisms in PDLIM7, PLN and SYNPO2 were associated with surrogate markers 
of atherosclerosis in high-risk subjects without symptoms of cardiovascular disease. Our 
work emphasizes the significance of SMC phenotypic modulation in atherosclerosis. In 
addition, these newly described SMC genes may improve definition of the phenotypic state of 
these cells in vascular disease and may be related to the capacity of SMCs to contribute to 
stabilizing processes in atherosclerotic lesions. 
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Supplementary	  Table	  I:	  Pathway	  analysis	  of	  downregulated	  genes	  in	  	  BiKE	  plaque	  microarrays	  
plaques	  vs.	  normal	  arteries	  (n=127+10) symptomatic	  vs.	  asymptomatic	  plaques	  (n=87+40)
Gene	  Ontology	  Function FDR Gene	  Ontology	  Function FDR
muscle	  system	  process 1.81E-­‐21 muscle	  contraction 1.20E-­‐06
muscle	  contraction 6.99E-­‐21 extracellular	  matrix 2.44E-­‐06
contractile	  fiber 1.67E-­‐10 muscle	  system	  process 2.44E-­‐06
actin	  cytoskeleton 2.54E-­‐10 muscle	  structure	  development 7.58E-­‐04
myofibril 3.79E-­‐10 proteinaceous	  extracellular	  matrix 2.18E-­‐03
adherens	  junction 2.93E-­‐09 actin	  cytoskeleton 2.56E-­‐03
cell-­‐substrate	  junction 1.05E-­‐07 structural	  constituent	  of	  muscle 1.67E-­‐02
extracellular	  matrix 1.80E-­‐07 kidney	  vasculature	  development 1.96E-­‐02
focal	  adhesion 5.49E-­‐07 contractile	  fiber	  part 3.21E-­‐02
regulation	  of	  muscle	  system	  process 6.14E-­‐07 muscle	  organ	  development 3.74E-­‐02
smooth	  muscle	  contraction 1.37E-­‐06
muscle	  structure	  development 1.66E-­‐06
costamere 3.16E-­‐06
regulation	  of	  muscle	  contraction 7.73E-­‐06
sarcomere 8.31E-­‐06
structural	  constituent	  of	  muscle 2.97E-­‐05
actin	  binding 4.58E-­‐05
actin-­‐mediated	  cell	  contraction 8.33E-­‐05
circulatory	  system	  process 1.43E-­‐04
actomyosin 1.55E-­‐04
muscle	  organ	  development 1.64E-­‐04
actin	  filament	  organization 1.93E-­‐04
actin	  filament-­‐based	  movement 4.22E-­‐04
cell	  junction	  assembly 6.14E-­‐04
stress	  fiber 7.99E-­‐04
angiogenesis 9.25E-­‐04
actin	  filament	  bundle 9.25E-­‐04
muscle	  cell	  differentiation 1.56E-­‐03
heart	  contraction 1.87E-­‐03
blood	  vessel	  development 2.56E-­‐03
blood	  circulation 3.59E-­‐03
regulation	  of	  heart	  contraction 6.61E-­‐03
extracellular	  matrix	  organization 6.98E-­‐03
extracellular	  structure	  organization 7.09E-­‐03
cell-­‐substrate	  adhesion 8.40E-­‐03
regulation	  of	  smooth	  muscle	  contraction 1.19E-­‐02
striated	  muscle	  cell	  differentiation 1.48E-­‐02
calcium	  ion	  transport 1.92E-­‐02
actin	  filament 3.50E-­‐02
actin-­‐myosin	  filament	  sliding 3.50E-­‐02
Supplementary	  Table	  II:	  Differential	  expression	  of	  candidate	  SMCs	  markers	  in	  microarrays	  	  from	  human	  
plaque	  tissues
BiKE	  plaque	  n=127	  vs.	  normal	  artery	  n=10
Gene	  symbol Gene	  name fold	  change	  (downregulation) p-­‐value
SYNPO2 synaptopodin	  2 0.052286779 <0.0001
SYNM synemin 0.190309568 <0.0001
LMOD1 leiomodin	  1 0.197674681 <0.0001
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 0.165801619 <0.0001
PLN phospholamban 0.311484008 <0.0001
BiKE	  symptomatic	  n=87	  	  vs.	  asymptomatic	  n=40
Gene	  symbol Gene	  name fold	  change	  (downregulation) p-­‐value
SYNPO2 synaptopodin	  2 0.773175056 <0.0001
SYNM synemin 0.80189319 0.000295
LMOD1 leiomodin	  1 0.698721288 <0.0001
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 0.663535703 <0.0001
PLN phospholamban 0.660982509 <0.0001
BiKE	  plaque	  n=50	  vs.	  normal	  arteries	  n=5
Gene	  symbol Gene	  name fold	  change	  (downregulation) p-­‐value
SYNPO2 synaptopodin	  2 0.933482318 0.0272086
SYNM synemin 0.208883436 <	  0.0001
LMOD1 leiomodin	  1 0.395286338 0.000341588
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 0.79699689 0.00220495
PLN phospholamban 0.432496391 0.00469566
Saksi	  et	  al.	  dataset	  symptomatic	  n=12	  vs.	  asymptomatic	  n=9
Gene	  symbol Gene	  name fold	  change	  (downregulation) p-­‐value
SYNPO2 synaptopodin	  2 not	  found	  in	  dataset not	  found	  in	  dataset
SYNM synemin 0.348534 0.034546
LMOD1 leiomodin	  1 0.574446 0.0371126
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 0.331987 0.045662
PLN phospholamban 0.316845 0.040389
GSE43292	  dataset:	  carotid	  plaques	  n=32	  vs.	  matched	  adjacent	  tissue	  n=32
Gene	  symbol Gene	  name fold	  change	  (downregulation) p-­‐value
SYNPO2 synaptopodin	  2 0.534923689 0.0000761
SYNM synemin 0.599601518 0.0000835
LMOD1 leiomodin	  1 0.531384871 0.0000753
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 0.735601461 0.0016719
PLN phospholamban 0.479262555 0.0000984
GSE23303	  dataset:	  carotid	  plaque	  SMCs-­‐rich	  regions	  n=3	  vs.	  macrophage-­‐rich	  regions	  n=3,	  isolated	  by	  
laser	  capture	  microscopy	  
Gene	  symbol Gene	  name fold	  change	  (upregulation) p-­‐value
SYNPO2 synaptopodin	  2 10.1246213 0.006597
SYNM synemin 15.8675976 0.0017057
LMOD1 leiomodin	  1 13.8065034 0.0026328
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 11.6151913 0.0044314
PLN phospholamban 12.1981667 0.0038319
ACTA2 smooth	  muscle	  actin 0.0535719 0.9481788
MYH11 myosin	  heavy	  chain	  11 7.7847823 0.0135346
MYOCD myocardin 33.1384268 0.0001432
CNN1 calponin 14.2453287 0.0023906
Suppementary	  Table	  III:	  Transcriptomic	  and	  proteomic	  expression	  correlations	  for	  candidate	  and	  typical	  SMCs	  markers
BiKE	  human	  carotid	  plaques	  microarrays
LMOD1	   SYNPO2 SYNM PDLIM7 PLN
SMC	  markers Pearson	  r p-­‐value Pearson	  	  r p-­‐value Pearson	  	  r p-­‐value Pearson	  r p-­‐value Pearson	  r p-­‐value
ACTA2 0.7238 <	  0.0001 0.6983 <	  0.0001 0.7643 <	  0.0001 0.3916 <	  0.0001 0.7841 <	  0.0001
SMTN	   0.7069 <	  0.0001 0.5411 <	  0.0001 0.6398 <	  0.0001 0.5964 <	  0.0001 0.651 <	  0.0001
CNN1 0.7583 <	  0.0001 0.6011 <	  0.0001 0.6797 <	  0.0001 0.6227 <	  0.0001 0.6574 <	  0.0001
MYH11 0.7636 <	  0.0001 0.7519 <	  0.0001 0.7124 <	  0.0001 0.5862 <	  0.0001 0.8231 <	  0.0001
MYOCD	   0.638 <	  0.0001 0.6493 <	  0.0001 0.6402 <	  0.0001 0.483 <	  0.0001 0.7223 <	  0.0001
BiKE	  human	  carotid	  plaques	  mass	  spectrometry,	  correlation	  matrix
Pearson	  r SMA CNN1 MYH11 PDLIM7 LMOD1 SYNPO2 SYNM
SMA 0.9682 0.9373 0.8936 0.9287 0.8631 0.4491
CNN1 0.9682 0.9721163 0.872647 0.9405631 0.877894 0.4386379
MYH11 0.9373 0.972116 0.822397 0.9350476 0.867897 0.448287
PDLIM7 0.8936 0.872647 0.8223968 0.8561276 0.753346 0.522256
LMOD1 0.9287 0.940563 0.9350476 0.856128 0.922575 0.4888232
SYNPO2 0.8631 0.877894 0.8678971 0.753346 0.9225745 0.418021
SYNM 0.4491 0.438638 0.448287 0.522256 0.4888232 0.418021
p-­‐value SMA CNN1 MYH11 PDLIM7 LMOD1 SYNPO2 SYNM
SMA <	  0.0001 <	  0.0001 <	  0.0001 <	  0.0001 <	  0.0001 0.0615
CNN1 <	  0.0001 1.68E-­‐11 2.32E-­‐06 6.49E-­‐09 1.68E-­‐06 0.068615
MYH11 <	  0.0001 1.68E-­‐11 2.8E-­‐05 1.30E-­‐08 3.06E-­‐06 0.0620676
PDLIM7 <	  0.0001 2.32E-­‐06 2.804E-­‐05 5.819E-­‐06 0.000307 0.0261917
LMOD1 <	  0.0001 6.49E-­‐09 1.30E-­‐08 5.82E-­‐06 5.08E-­‐08 0.0395374
SYNPO2 <	  0.0001 1.68E-­‐06 3.056E-­‐06 0.000307 5.08E-­‐08 0.0842999
SYNM 0.0615 0.068615 0.0620676 0.026192 0.0395374 0.0843
Rat	  carotid	  artery	  injury	  microarrays
LMOD1	   SYNPO2 SYNM PDLIM7 PLN
SMC	  markers Pearson	  r p-­‐value Pearson	  	  r p-­‐value Pearson	  	  r p-­‐value Pearson	  r p-­‐value Pearson	  r p-­‐value
ACTA2	   0.6576 <	  0.0001 0.6612 <	  0.0001 0.6566 <	  0.0001 0.713 <	  0.0001 0.6666 <	  0.0001
SMTN	   0.9676 <	  0.0001 0.8661 <	  0.0001 0.7919 <	  0.0001 0.6891 <	  0.0001 0.8093 <	  0.0001
CNN1	   0.8999 <	  0.0001 0.8239 <	  0.0001 0.7569 <	  0.0001 0.7544 <	  0.0001 0.8354 <	  0.0001
MYH11	   0.9498 <	  0.0001 0.9363 <	  0.0001 0.8831 <	  0.0001 0.7108 <	  0.0001 0.792 <	  0.0001
MYOCD 0.7214 <	  0.0001 0.7761 <	  0.0001 0.7551 <	  0.0001 0.8025 <	  0.0001 0.7124 <	  0.0001
LMOD1	   SYNPO2 SYNM PDLIM7 PLN
Cytokines Pearson	  r p-­‐value Pearson	  	  r p-­‐value Pearson	  	  r p-­‐value Pearson	  r p-­‐value Pearson	  r p-­‐value
PDGFB -­‐0.3217 0.0156 -­‐0.5135 <	  0.0001 -­‐0.5547 <	  0.0001 -­‐0.5472 <	  0.0001 -­‐0.2644 0.049
IGF1 -­‐0.365 0.0057 -­‐0.5846 <	  0.0001 -­‐0.6443 <	  0.0001 -­‐0.7011 <	  0.0001 -­‐0.2387 0.05
TGFB1 -­‐0.56 <	  0.0001 -­‐0.4824 0.0002 -­‐0.4911 <	  0.0001 -­‐0.4546 0.0004 -­‐0.703 <	  0.0001
Suppementary	  Table	  IV:	  Transcriptomic	  analysis	  of	  SMCs	  markers	  in	  mouse	  model	  of	  atherosclerotic	  plaque	  rupture
Ligation	  VS	  Normal
Gene	  Symbol Fold	  Change	   p-­‐value FDR	  
Pdlim7 -­‐4.25 0.000001 0.000056
Synpo2 -­‐114.39 9.85E-­‐11 2.33E-­‐07
Pln -­‐4.29 7.69E-­‐07 0.000038
Lmod1 -­‐45.05 2.32E-­‐08 0.000003
Synm -­‐1.46 0.023435 0.106494
Rupture	  vs	  Stable
Gene	  Symbol Fold	  Change	   	  p-­‐value	   FDR	  
Pdlim7 -­‐1.25 0.029730 0.494775
Synpo2 -­‐1.61 0.060025 0.606094
Pln -­‐1.02 0.679074 0.986442
Lmod1 -­‐1.99 0.017015 0.436322
Synm -­‐1.09 0.353552 0.922700
Supplementary	  Table	  V:	  RNAseq	  data	  comparing	  gene	  expression	  in	  human	  coronary	  artery	  SMCs	  cultured	  in	  serum	  vs.	  no	  serum	  
Gene	  symbol Gene	  name fold	  change p-­‐value
SYNPO2 synaptopodin	  2 0.468746646 5.55E-­‐17
LMOD1 leiomodin	  1 0.419018145 1.22E-­‐30
PDLIM7 PDZ	  and	  LIM	  domain	  containing	  7 0.715969101 0.00416383
PLN phospholamban 0.323119589 6.7E-­‐09
SYNM synemin 0.671463478 4.96E-­‐05
Supplementary	  Table	  VI:	  ChIP	  seq	  data	  from	  primary	  human	  SMCs	  for	  H3K27ac	  active	  histone	  modification
Gene chr start end strand
Normalized	  
Tag	  Count
region	  
size	  
findPeaks	  
Score
Total	  
Tags
Control	  Tags	  
(normalized	  
to	  IP	  Exp)
Fold	  
Change	  vs	  
Control
p-­‐value	  vs	  
Control
Clonal	  Fold	  
Change
LMOD1 chr1 2E+08 201915441 + 21 1000 37 38.5 7.4 5.19 1.71E-­‐15 0.97
SYNPO2 chr4 1.2E+08 119772533 + 23.2 1515 41 54.2 9.5 5.71 2.45E-­‐23 0.97
SYNPO2 chr4 1.2E+08 119813078 + 14.8 1000 39 34.7 8 4.33 7.45E-­‐12 0.98
SYNPO2 chr4 1.2E+08 119827702 + 90.2 2456 89.5 211.1 43 4.91 5.45E-­‐75 0.94
SYNPO2 chr4 1.2E+08 119833050 + 42.3 2039 42 99.1 22 4.51 3.04E-­‐33 0.96
SYNPO2 chr4 1.2E+08 119842101 + 226.8 5320 43.5 531.2 71 7.48 1.17E-­‐266 0.92
SYNPO2 chr4 1.2E+08 119869901 + 63.2 2574 44 148 24.5 6.04 4.23E-­‐64 0.96
SYNPO2 chr4 1.2E+08 119878452 + 93.6 3652 62.5 219.1 42.5 5.16 1.72E-­‐81 0.96
SYNPO2 chr4 1.2E+08 119906168 + 47.1 2008 82.5 110.2 23 4.79 5.02E-­‐39 0.97
SYNPO2 chr4 1.2E+08 119912066 + 87.3 3118 35.5 204.5 47.5 4.3 2.56E-­‐63 0.94
PDLIM7 chr5 1.8E+08 176924718 + 305.2 4529 89 714.8 143 5 4.19E-­‐253 0.92
PLN chr6 1.2E+08 118859467 + 20.5 1608 32 48 11 4.36 1.68E-­‐16 0.97
PLN chr6 1.2E+08 118869039 + 28.3 1775 45.5 66.2 10.5 6.31 1.50E-­‐30 0.97
PLN chr6 1.2E+08 118873479 + 30.6 1250 72 71.6 16 4.47 5.28E-­‐24 0.96
PLN chr6 1.2E+08 118881170 + 17.8 1000 36.5 41.8 8.5 4.92 9.72E-­‐16 0.98
SYNM ch15 1E+08 99710294 + 24.3 1000 63.5 56.9 13 4.38 9.88E-­‐19 0.98
Supplementary	  Table	  VII:	  Putative	  transcription	  factors	  (TF)	  binding	  motifs	  enrichment	  analysis	  of	  candidate	  SMCs	  genes	  by	  MotifMap
Location strand FDR Motif	  ID TF	  Name Gene Distance	  from	  transcription	  start	  (bp) Region
chr5:176932292..176932299 -­‐ 0 M00468 AP-­‐2rep PDLIM7 -­‐7697 Upstream
chr5:176932115..176932121 + 0 M00704 TEF-­‐1 PDLIM7 -­‐7513 Upstream
chr5:176931912..176931919 -­‐ 0 M00468 AP-­‐2rep PDLIM7 -­‐7317 Upstream
chr5:176930474..176930481 -­‐ 0 M00468 AP-­‐2rep PDLIM7 -­‐5879 Upstream
chr5:176928139..176928159 -­‐ 0 M01259 CTCF PDLIM7 -­‐3557 Upstream
chr5:176928137..176928157 -­‐ 0 M01200 CTCF PDLIM7 -­‐3555 Upstream
chr5:176928137..176928156 -­‐ 0 MA0139 CTCF PDLIM7 -­‐3554 Upstream
chr5:176928137..176928156 -­‐ 0 LM2_CTCF CTCF PDLIM7 -­‐3554 Upstream
chr5:176928041..176928047 -­‐ 0 M00704 TEF-­‐1 PDLIM7 -­‐3445 Upstream
chr5:176924073..176924079 -­‐ 0 M00704 TEF-­‐1 PDLIM7 523 Downstream
chr5:176923860..176923873 + 0 M00517 AP-­‐1 PDLIM7 742 Downstream
chr5:176923605..176923619 -­‐ 0 M01196 CTF1 PDLIM7 983 Downstream
chr5:176922810..176922831 + 0 M00512 PPARgamma:RXRalpha PDLIM7 1792 Downstream
chr5:176922363..176922373 -­‐ 0 M00761 p53	  decamer PDLIM7 2229 Downstream
chr5:176921779..176921792 + 0 M00517 AP-­‐1 PDLIM7 2823 Downstream
chr5:176920471..176920477 + 0 M00704 TEF-­‐1 PDLIM7 4131 Downstream
chr5:176919482..176919489 -­‐ 0 M00468 AP-­‐2rep PDLIM7 5113 Downstream
chr5:176918675..176918694 + 0 MA0139 CTCF PDLIM7 5927 Downstream
chr5:176918674..176918694 + 0 M01200 CTCF PDLIM7 5928 Downstream
chr5:176917820..176917826 + 0 M00704 TEF-­‐1 PDLIM7 6782 Downstream
chr5:176917140..176917147 -­‐ 0 M00468 AP-­‐2rep PDLIM7 7455 Downstream
chr5:176916962..176916969 -­‐ 0 M00468 AP-­‐2rep PDLIM7 7633 Downstream
chr5:176922239..176922248 -­‐ 0.003 M01705 TCF4 PDLIM7 2354 Downstream
chr5:176918672..176918692 + 0.003 M01259 CTCF PDLIM7 5930 Downstream
chr5:176931920..176931928 -­‐ 0.004 M00973 E2A PDLIM7 -­‐7326 Upstream
chr5:176922029..176922048 -­‐ 0.007 MA0139 CTCF PDLIM7 2554 Downstream
chr5:176921780..176921791 -­‐ 0.008 M00174 AP-­‐1 PDLIM7 2811 Downstream
chr5:176919526..176919533 -­‐ 0.009 M01709 MAFA PDLIM7 5069 Downstream
chr5:176922580..176922586 -­‐ 0.013 M01287 Neuro	  D PDLIM7 2016 Downstream
chr5:176922580..176922586 + 0.013 M01287 Neuro	  D PDLIM7 2022 Downstream
chr5:176922388..176922394 + 0.013 M01287 Neuro	  D PDLIM7 2214 Downstream
chr5:176922388..176922394 -­‐ 0.013 M01287 Neuro	  D PDLIM7 2208 Downstream
chr5:176919524..176919532 + 0.013 M00698 HEB PDLIM7 5078 Downstream
chr5:176922814..176922827 + 0.015 M00762 PPAR,	  HNF-­‐4,	  COUP,	  RAR PDLIM7 1788 Downstream
chr5:176922031..176922051 -­‐ 0.016 M01259 CTCF PDLIM7 2551 Downstream
chr5:176922029..176922048 -­‐ 0.016 LM2_CTCF CTCF PDLIM7 2554 Downstream
chr5:176922029..176922049 -­‐ 0.016 M01200 CTCF PDLIM7 2553 Downstream
chr5:176919814..176919820 -­‐ 0.016 M01287 Neuro	  D PDLIM7 4782 Downstream
chr5:176919814..176919820 + 0.016 M01287 Neuro	  D PDLIM7 4788 Downstream
chr5:176930411..176930418 + 0.017 M01709 MAFA PDLIM7 -­‐5809 Upstream
chr5:176924267..176924278 + 0.017 M00174 AP-­‐1 PDLIM7 335 Downstream
chr5:176916693..176916699 + 0.017 M01287 Neuro	  D PDLIM7 7909 Downstream
chr5:176916693..176916699 -­‐ 0.017 M01287 Neuro	  D PDLIM7 7903 Downstream
chr5:176918541..176918547 -­‐ 0.019 M01287 Neuro	  D PDLIM7 6055 Downstream
chr5:176918541..176918547 + 0.019 M01287 Neuro	  D PDLIM7 6061 Downstream
chr5:176922388..176922395 + 0.02 M00644 LBP-­‐1 PDLIM7 2214 Downstream
chr5:176922814..176922827 -­‐ 0.021 M00764 HNF4	  direct	  repeat	  1 PDLIM7 1775 Downstream
chr5:176920298..176920304 + 0.021 M01287 Neuro	  D PDLIM7 4304 Downstream
chr5:176920298..176920304 -­‐ 0.021 M01287 Neuro	  D PDLIM7 4298 Downstream
chr5:176916692..176916699 -­‐ 0.021 M00644 LBP-­‐1 PDLIM7 7903 Downstream
chr5:176924468..176924475 + 0.023 M01709 MAFA PDLIM7 134 Downstream
chr5:176921287..176921294 -­‐ 0.024 M01709 MAFA PDLIM7 3308 Downstream
chr5:176919814..176919821 + 0.025 M00644 LBP-­‐1 PDLIM7 4788 Downstream
chr5:176919813..176919820 -­‐ 0.025 M00644 LBP-­‐1 PDLIM7 4782 Downstream
chr5:176922820..176922827 -­‐ 0.028 M01269 NURR1 PDLIM7 1775 Downstream
chr5:176923861..176923872 -­‐ 0.029 M00174 AP-­‐1 PDLIM7 730 Downstream
chr5:176917104..176917110 -­‐ 0.03 MA0095 YY1 PDLIM7 7492 Downstream
chr5:176917095..176917101 + 0.03 MA0095 YY1 PDLIM7 7507 Downstream
chr5:176932011..176932018 + 0.034 M01207 ETS2 PDLIM7 -­‐7409 Upstream
chr5:176921439..176921450 -­‐ 0.038 M00174 AP-­‐1 PDLIM7 3152 Downstream
chr5:176921722..176921729 -­‐ 0.039 M01269 NURR1 PDLIM7 2873 Downstream
chr5:176918415..176918427 + 0.045 M00414 AREB6 PDLIM7 6187 Downstream
chr5:176922662..176922668 + 0.048 MA0095 YY1 PDLIM7 1940 Downstream
chr5:176922445..176922452 -­‐ 0.051 M01207 ETS2 PDLIM7 2150 Downstream
chr5:176923863..176923871 + 0.054 M01267 FRA1 PDLIM7 739 Downstream
chr5:176922377..176922384 + 0.054 M01207 ETS2 PDLIM7 2225 Downstream
chr5:176921782..176921790 + 0.054 M01267 FRA1 PDLIM7 2820 Downstream
chr5:176921441..176921449 + 0.054 M01267 FRA1 PDLIM7 3161 Downstream
chr5:176921604..176921611 -­‐ 0.055 M01207 ETS2 PDLIM7 2991 Downstream
chr5:176930680..176930687 + 0.056 M01268 FXR PDLIM7 -­‐6078 Upstream
chr5:176922814..176922827 -­‐ 0.061 M00765 COUP	  direct	  repeat	  1 PDLIM7 1775 Downstream
chr5:176920199..176920205 + 0.061 MA0095 YY1 PDLIM7 4403 Downstream
chr5:176930532..176930539 + 0.062 M01207 ETS2 PDLIM7 -­‐5930 Upstream
chr5:176917089..176917096 -­‐ 0.062 M01207 ETS2 PDLIM7 7506 Downstream
chr5:176918771..176918777 -­‐ 0.067 MA0095 YY1 PDLIM7 5825 Downstream
chr5:176922237..176922243 + 0.068 MA0095 YY1 PDLIM7 2365 Downstream
chr5:176916870..176916877 + 0.068 M01207 ETS2 PDLIM7 7732 Downstream
chr5:176920548..176920554 -­‐ 0.072 MA0095 YY1 PDLIM7 4048 Downstream
chr5:176920746..176920752 + 0.074 MA0095 YY1 PDLIM7 3856 Downstream
chr5:176922814..176922828 + 0.076 M01031 HNF4 PDLIM7 1788 Downstream
chr5:176924328..176924335 -­‐ 0.077 M01207 ETS2 PDLIM7 267 Downstream
chr5:176928485..176928492 -­‐ 0.078 M01207 ETS2 PDLIM7 -­‐3890 Upstream
chr5:176923605..176923619 -­‐ 0.078 MA0119 TLX1::NFIC PDLIM7 983 Downstream
chr5:176921578..176921586 + 0.081 M00497 STAT3 PDLIM7 3024 Downstream
chr5:176930620..176930628 + 0.083 M00498 STAT4 PDLIM7 -­‐6018 Upstream
chr5:176924133..176924141 -­‐ 0.089 M00500 STAT6 PDLIM7 461 Downstream
chr5:176924268..176924279 -­‐ 0.09 M00037 NF-­‐E2 PDLIM7 323 Downstream
chr5:176924268..176924277 + 0.09 M00199 AP-­‐1 PDLIM7 334 Downstream
chr5:176923862..176923871 + 0.101 M00199 AP-­‐1 PDLIM7 740 Downstream
chr5:176921781..176921790 + 0.101 M00199 AP-­‐1 PDLIM7 2821 Downstream
chr5:176921778..176921793 + 0.102 M00495 Bach1 PDLIM7 2824 Downstream
chr5:176921440..176921449 + 0.102 M00199 AP-­‐1 PDLIM7 3162 Downstream
chr5:176928349..176928356 -­‐ 0.112 M01268 FXR PDLIM7 -­‐3754 Upstream
chr5:176921780..176921791 + 0.113 M00490 Bach2 PDLIM7 2822 Downstream
chr5:176921781..176921792 -­‐ 0.118 M00037 NF-­‐E2 PDLIM7 2810 Downstream
chr5:176923859..176923874 + 0.121 M00495 Bach1 PDLIM7 743 Downstream
chr5:176918476..176918484 + 0.122 M00658 PU.1 PDLIM7 6126 Downstream
chr5:176923605..176923622 + 0.124 M00806 NF-­‐1 PDLIM7 997 Downstream
chr5:176923861..176923872 + 0.15 M00490 Bach2 PDLIM7 741 Downstream
chr5:176924268..176924277 + 0.184 M00925 AP-­‐1 PDLIM7 334 Downstream
chr5:176922441..176922457 + 0.186 M00007 Elk-­‐1 PDLIM7 2161 Downstream
chr5:176919869..176919876 -­‐ 0.217 M00750 HMG	  IY PDLIM7 4726 Downstream
chr5:176920352..176920359 -­‐ 0.218 M00750 HMG	  IY PDLIM7 4243 Downstream
chr5:176932012..176932022 + 0.293 M01119 KAISO PDLIM7 -­‐7410 Upstream
chr5:176922817..176922823 + 0.294 M00805 LEF1 PDLIM7 1785 Downstream
chr5:176923933..176923948 -­‐ 0.301 M00215 SRF PDLIM7 654 Downstream
chr5:176922687..176922702 -­‐ 0.301 M00215 SRF PDLIM7 1900 Downstream
chr5:176924628..176924634 -­‐ 0.303 M00805 LEF1 PDLIM7 -­‐32 Upstream
chr5:176924704..176924711 -­‐ 0.307 M01718 NFAT2 PDLIM7 -­‐109 Upstream
chr5:176923419..176923427 -­‐ 0.314 M00493 STAT5A PDLIM7 1175 Downstream
chr5:176916934..176916941 -­‐ 0.322 M01718 NFAT2 PDLIM7 7661 Downstream
chr5:176922699..176922709 -­‐ 0.328 M00051 NF-­‐kappaB	  (p50) PDLIM7 1893 Downstream
chr5:176919404..176919419 -­‐ 0.345 M00984 PEBP PDLIM7 5183 Downstream
chr5:176932129..176932135 + 0.362 M00805 LEF1 PDLIM7 -­‐7527 Upstream
chr5:176923937..176923952 + 0.378 M00252 TATA PDLIM7 665 Downstream
chr5:176918405..176918417 + 0.381 MA0155 INSM1 PDLIM7 6197 Downstream
chr5:176920586..176920592 -­‐ 0.399 M00805 LEF1 PDLIM7 4010 Downstream
chr5:176920553..176920559 -­‐ 0.4 M00805 LEF1 PDLIM7 4043 Downstream
chr5:176922241..176922247 + 0.403 M00805 LEF1 PDLIM7 2361 Downstream
chr5:176920478..176920484 -­‐ 0.405 M00805 LEF1 PDLIM7 4118 Downstream
chr5:176930407..176930414 + 0.407 M01665 IRF8 PDLIM7 -­‐5805 Upstream
chr5:176923397..176923404 -­‐ 0.412 M01733 MZF1 PDLIM7 1198 Downstream
chr5:176920225..176920231 -­‐ 0.414 M00805 LEF1 PDLIM7 4371 Downstream
chr5:176918150..176918157 + 0.429 M01733 MZF1 PDLIM7 6452 Downstream
chr5:176921638..176921645 + 0.434 M01733 MZF1 PDLIM7 2964 Downstream
chr5:176921785..176921791 -­‐ 0.44 M01227 MAFB PDLIM7 2811 Downstream
chr5:176932112..176932118 + 0.449 MA0056 MZF1_1-­‐4 PDLIM7 -­‐7510 Upstream
chr5:176923954..176923960 + 0.455 M01227 MAFB PDLIM7 648 Downstream
chr5:176922871..176922878 + 0.461 M01733 MZF1 PDLIM7 1731 Downstream
chr5:176918562..176918569 + 0.471 MA0133 BRCA1 PDLIM7 6040 Downstream
chr5:176923398..176923404 -­‐ 0.472 MA0056 MZF1_1-­‐4 PDLIM7 1198 Downstream
chr5:176922006..176922012 + 0.472 M01227 MAFB PDLIM7 2596 Downstream
chr5:176931707..176931713 -­‐ 0.473 M01227 MAFB PDLIM7 -­‐7111 Upstream
chr5:176918150..176918156 + 0.474 MA0056 MZF1_1-­‐4 PDLIM7 6452 Downstream
chr5:176921638..176921644 + 0.477 MA0056 MZF1_1-­‐4 PDLIM7 2964 Downstream
chr5:176923933..176923952 -­‐ 0.483 M01007 SRF PDLIM7 650 Downstream
chr5:176922871..176922877 + 0.484 MA0056 MZF1_1-­‐4 PDLIM7 1731 Downstream
chr5:176923935..176923949 + 0.487 M00186 SRF PDLIM7 667 Downstream
chr5:176922091..176922098 -­‐ 0.488 M01733 MZF1 PDLIM7 2504 Downstream
chr5:176918335..176918342 + 0.492 M01733 MZF1 PDLIM7 6267 Downstream
chr5:176922689..176922707 + 0.493 M01257 SRF PDLIM7 1913 Downstream
chr5:176922452..176922458 -­‐ 0.498 MA0056 MZF1_1-­‐4 PDLIM7 2144 Downstream
chr1:201916734..201916743 -­‐ 0 M01721 PUR1 LMOD1 -­‐1027 Upstream
chr1:201912172..201912181 + 0 M01721 PUR1 LMOD1 3544 Downstream
chr1:201921129..201921135 -­‐ 0 M00704 TEF-­‐1 LMOD1 -­‐5419 Upstream
chr1:201916951..201916957 + 0 M00704 TEF-­‐1 LMOD1 -­‐1235 Upstream
chr1:201915796..201915802 -­‐ 0 M00704 TEF-­‐1 LMOD1 -­‐86 Upstream
chr1:201914865..201914871 + 0 M00704 TEF-­‐1 LMOD1 851 Downstream
chr1:201914021..201914027 -­‐ 0 M00704 TEF-­‐1 LMOD1 1689 Downstream
chr1:201908243..201908249 -­‐ 0 M00704 TEF-­‐1 LMOD1 7467 Downstream
chr1:201914483..201914492 + 0.002 M00927 AP-­‐4 LMOD1 1233 Downstream
chr1:201912617..201912625 + 0.004 M00973 E2A LMOD1 3099 Downstream
chr1:201907756..201907764 + 0.004 M00973 E2A LMOD1 7960 Downstream
chr1:201910955..201910961 -­‐ 0.004 M01287 Neuro	  D LMOD1 4755 Downstream
chr1:201910955..201910961 + 0.004 M01287 Neuro	  D LMOD1 4761 Downstream
chr1:201910955..201910962 + 0.007 M00644 LBP-­‐1 LMOD1 4761 Downstream
chr1:201910822..201910829 -­‐ 0.009 M01709 MAFA LMOD1 4887 Downstream
chr1:201911162..201911169 + 0.009 M01131 SOX10 LMOD1 4554 Downstream
chr1:201908980..201908986 + 0.011 M01287 Neuro	  D LMOD1 6736 Downstream
chr1:201908980..201908986 -­‐ 0.011 M01287 Neuro	  D LMOD1 6730 Downstream
chr1:201907966..201907972 + 0.012 M01287 Neuro	  D LMOD1 7750 Downstream
chr1:201907966..201907972 -­‐ 0.012 M01287 Neuro	  D LMOD1 7744 Downstream
chr1:201914272..201914279 -­‐ 0.012 M01131 SOX10 LMOD1 1437 Downstream
chr1:201919156..201919162 -­‐ 0.015 M01287 Neuro	  D LMOD1 -­‐3446 Upstream
chr1:201919156..201919162 + 0.015 M01287 Neuro	  D LMOD1 -­‐3440 Upstream
chr1:201914259..201914266 -­‐ 0.015 M01131 SOX10 LMOD1 1450 Downstream
chr1:201914792..201914799 + 0.017 M01131 SOX10 LMOD1 924 Downstream
chr1:201918737..201918743 -­‐ 0.018 M01287 Neuro	  D LMOD1 -­‐3027 Upstream
chr1:201918737..201918743 + 0.018 M01287 Neuro	  D LMOD1 -­‐3021 Upstream
chr1:201909078..201909085 + 0.022 M01131 SOX10 LMOD1 6638 Downstream
chr1:201914485..201914491 + 0.025 M01287 Neuro	  D LMOD1 1231 Downstream
chr1:201914485..201914491 -­‐ 0.025 M01287 Neuro	  D LMOD1 1225 Downstream
chr1:201909006..201909013 -­‐ 0.025 M01131 SOX10 LMOD1 6703 Downstream
chr1:201918644..201918650 + 0.026 M01287 Neuro	  D LMOD1 -­‐2928 Upstream
chr1:201918644..201918650 -­‐ 0.026 M01287 Neuro	  D LMOD1 -­‐2934 Upstream
chr1:201914485..201914492 + 0.027 M00644 LBP-­‐1 LMOD1 1231 Downstream
chr1:201912570..201912577 -­‐ 0.036 M01269 NURR1 LMOD1 3139 Downstream
chr1:201916563..201916570 + 0.043 M01268 FXR LMOD1 -­‐847 Upstream
chr1:201909232..201909238 + 0.043 MA0095 YY1 LMOD1 6484 Downstream
chr1:201911768..201911775 -­‐ 0.049 M01269 NURR1 LMOD1 3941 Downstream
chr1:201919064..201919072 -­‐ 0.051 M00926 AP-­‐1 LMOD1 -­‐3356 Upstream
chr1:201913597..201913605 + 0.054 M00498 STAT4 LMOD1 2119 Downstream
chr1:201918648..201918655 + 0.061 M01269 NURR1 LMOD1 -­‐2932 Upstream
chr1:201920656..201920663 + 0.074 M01207 ETS2 LMOD1 -­‐4940 Upstream
chr1:201913795..201913803 + 0.074 M00497 STAT3 LMOD1 1921 Downstream
chr1:201910756..201910764 + 0.074 M00500 STAT6 LMOD1 4960 Downstream
chr1:201918920..201918927 -­‐ 0.078 M01207 ETS2 LMOD1 -­‐3211 Upstream
chr1:201915982..201915988 + 0.092 M01033 HNF4 LMOD1 -­‐266 Upstream
chr1:201916513..201916521 -­‐ 0.095 M00658 PU.1 LMOD1 -­‐805 Upstream
chr1:201914883..201914891 + 0.095 M01308 SOX4 LMOD1 833 Downstream
chr1:201916737..201916743 -­‐ 0.097 M01033 HNF4 LMOD1 -­‐1027 Upstream
chr1:201922573..201922581 + 0.11 M01308 SOX4 LMOD1 -­‐6857 Upstream
chr1:201913435..201913442 -­‐ 0.149 M00750 HMG	  IY LMOD1 2274 Downstream
chr1:201912172..201912178 + 0.164 M01033 HNF4 LMOD1 3544 Downstream
chr1:201916603..201916614 -­‐ 0.171 M00691 ATF1 LMOD1 -­‐898 Upstream
chr1:201916680..201916687 + 0.177 M01718 NFAT2 LMOD1 -­‐964 Upstream
chr1:201908626..201908635 + 0.178 M00792 SMAD LMOD1 7090 Downstream
chr1:201913748..201913754 + 0.18 M01033 HNF4 LMOD1 1968 Downstream
chr1:201912621..201912627 -­‐ 0.187 M01033 HNF4 LMOD1 3089 Downstream
chr1:201911125..201911132 + 0.19 M01665 IRF8 LMOD1 4591 Downstream
chr1:201915794..201915806 + 0.194 M01305 TEF LMOD1 -­‐78 Upstream
chr1:201922852..201922859 + 0.2 M00799 Myc LMOD1 -­‐7136 Upstream
chr1:201915783..201915790 -­‐ 0.205 M01665 IRF8 LMOD1 -­‐74 Upstream
chr1:201908586..201908592 + 0.216 M01033 HNF4 LMOD1 7130 Downstream
chr1:201920688..201920694 + 0.228 M01033 HNF4 LMOD1 -­‐4972 Upstream
chr1:201916850..201916857 -­‐ 0.252 M00240 Nkx2-­‐5 LMOD1 -­‐1141 Upstream
chr1:201915794..201915806 + 0.256 MA0090 TEAD1 LMOD1 -­‐78 Upstream
chr1:201915793..201915813 + 0.267 M00034 p53 LMOD1 -­‐77 Upstream
chr1:201916563..201916569 + 0.282 M01032 HNF4 LMOD1 -­‐847 Upstream
chr1:201908151..201908157 + 0.293 M00805 LEF1 LMOD1 7565 Downstream
chr1:201915793..201915813 -­‐ 0.293 M00034 p53 LMOD1 -­‐97 Upstream
chr1:201910853..201910859 + 0.303 M01032 HNF4 LMOD1 4863 Downstream
chr1:201914640..201914648 + 0.319 M00493 STAT5A LMOD1 1076 Downstream
chr1:201910514..201910521 + 0.329 M01665 IRF8 LMOD1 5202 Downstream
chr1:201916781..201916795 -­‐ 0.343 M00209 NF-­‐Y LMOD1 -­‐1079 Upstream
chr1:201910655..201910671 -­‐ 0.359 M01436 Crx LMOD1 5045 Downstream
chr1:201911221..201911227 + 0.386 M01227 MAFB LMOD1 4495 Downstream
chr1:201919399..201919405 + 0.387 M00805 LEF1 LMOD1 -­‐3683 Upstream
chr1:201913577..201913583 + 0.404 MA0056 MZF1_1-­‐4 LMOD1 2139 Downstream
chr1:201907806..201907812 + 0.406 M00805 LEF1 LMOD1 7910 Downstream
chr1:201910990..201910996 -­‐ 0.426 MA0056 MZF1_1-­‐4 LMOD1 4720 Downstream
chr1:201911291..201911298 -­‐ 0.435 M01733 MZF1 LMOD1 4418 Downstream
chr1:201916848..201916859 -­‐ 0.435 M00220 SREBP-­‐1 LMOD1 -­‐1143 Upstream
chr1:201923669..201923677 + 0.44 M00690 AP-­‐3 LMOD1 -­‐7953 Upstream
chr1:201910709..201910716 + 0.44 MA0133 BRCA1 LMOD1 5007 Downstream
chr1:201911489..201911495 -­‐ 0.442 M01032 HNF4 LMOD1 4221 Downstream
chr1:201915741..201915747 -­‐ 0.442 MA0056 MZF1_1-­‐4 LMOD1 -­‐31 Upstream
chr1:201908090..201908097 + 0.446 MA0133 BRCA1 LMOD1 7626 Downstream
chr1:201911048..201911056 + 0.446 M01111 RBP-­‐Jkappa LMOD1 4668 Downstream
chr1:201921408..201921415 -­‐ 0.451 M00240 Nkx2-­‐5 LMOD1 -­‐5699 Upstream
chr1:201911559..201911565 -­‐ 0.458 M01032 HNF4 LMOD1 4151 Downstream
chr1:201911738..201911744 + 0.465 MA0056 MZF1_1-­‐4 LMOD1 3978 Downstream
chr1:201914809..201914815 + 0.472 M01227 MAFB LMOD1 907 Downstream
chr1:201911292..201911298 -­‐ 0.475 MA0056 MZF1_1-­‐4 LMOD1 4418 Downstream
chr1:201922680..201922686 + 0.483 M01227 MAFB LMOD1 -­‐6964 Upstream
chr1:201920881..201920887 -­‐ 0.484 M01032 HNF4 LMOD1 -­‐5171 Upstream
chr1:201908993..201908999 + 0.486 M01227 MAFB LMOD1 6723 Downstream
chr6:118863507..118863513 -­‐ 0 M00704 TEF-­‐1 PLN -­‐5928 Upstream
chr6:118870473..118870479 + 0 M00704 TEF-­‐1 PLN 1032 Downstream
chr6:118871984..118871990 -­‐ 0 M00704 TEF-­‐1 PLN 2549 Downstream
chr6:118872852..118872858 + 0 M00704 TEF-­‐1 PLN 3411 Downstream
chr6:118872957..118872963 + 0 M00704 TEF-­‐1 PLN 3516 Downstream
chr6:118873929..118873935 -­‐ 0 M00704 TEF-­‐1 PLN 4494 Downstream
chr6:118868198..118868210 + 0.003 MA0055 Myf PLN -­‐1243 Upstream
chr6:118868201..118868207 + 0.004 M01287 Neuro	  D PLN -­‐1240 Upstream
chr6:118868201..118868207 -­‐ 0.004 M01287 Neuro	  D PLN -­‐1234 Upstream
chr6:118868200..118868207 -­‐ 0.006 M00644 LBP-­‐1 PLN -­‐1234 Upstream
chr6:118868201..118868208 + 0.006 M00644 LBP-­‐1 PLN -­‐1240 Upstream
chr6:118869945..118869952 -­‐ 0.01 M01709 MAFA PLN 511 Downstream
chr6:118862420..118862427 + 0.015 M01709 MAFA PLN -­‐7021 Upstream
chr6:118867849..118867855 + 0.015 M01287 Neuro	  D PLN -­‐1592 Upstream
chr6:118867849..118867855 -­‐ 0.015 M01287 Neuro	  D PLN -­‐1586 Upstream
chr6:118862694..118862701 -­‐ 0.019 M01709 MAFA PLN -­‐6740 Upstream
chr6:118869544..118869550 + 0.019 M01287 Neuro	  D PLN 103 Downstream
chr6:118869544..118869550 -­‐ 0.019 M01287 Neuro	  D PLN 109 Downstream
chr6:118869544..118869551 + 0.024 M00644 LBP-­‐1 PLN 103 Downstream
chr6:118867848..118867855 -­‐ 0.026 M00644 LBP-­‐1 PLN -­‐1586 Upstream
chr6:118874547..118874554 -­‐ 0.043 M01207 ETS2 PLN 5113 Downstream
chr6:118874476..118874483 + 0.043 M01268 FXR PLN 5035 Downstream
chr6:118866178..118866185 + 0.074 M01207 ETS2 PLN -­‐3263 Upstream
chr6:118862584..118862591 -­‐ 0.078 M01207 ETS2 PLN -­‐6850 Upstream
chr6:118874518..118874526 + 0.108 M01308 SOX4 PLN 5077 Downstream
chr6:118868010..118868017 -­‐ 0.112 M00750 HMG	  IY PLN -­‐1424 Upstream
chr6:118865459..118865467 -­‐ 0.112 M01308 SOX4 PLN -­‐3974 Upstream
chr6:118866338..118866345 -­‐ 0.147 M00750 HMG	  IY PLN -­‐3096 Upstream
chr6:118872621..118872628 -­‐ 0.155 M00750 HMG	  IY PLN 3187 Downstream
chr6:118873833..118873840 -­‐ 0.164 M00750 HMG	  IY PLN 4399 Downstream
chr6:118865663..118865670 -­‐ 0.177 M00750 HMG	  IY PLN -­‐3771 Upstream
chr6:118866030..118866037 -­‐ 0.179 M00750 HMG	  IY PLN -­‐3404 Upstream
chr6:118865543..118865550 + 0.2 M00799 Myc PLN -­‐3898 Upstream
chr6:118872445..118872453 + 0.2 M00671 TCF-­‐4 PLN 3004 Downstream
chr6:118869775..118869781 -­‐ 0.201 M00805 LEF1 PLN 340 Downstream
chr6:118869748..118869754 -­‐ 0.202 M00805 LEF1 PLN 313 Downstream
chr6:118871658..118871665 -­‐ 0.203 M00750 HMG	  IY PLN 2224 Downstream
chr6:118869369..118869383 -­‐ 0.203 M00209 NF-­‐Y PLN -­‐58 Upstream
chr6:118868181..118868196 + 0.203 M00215 SRF PLN -­‐1260 Upstream
chr6:118870829..118870835 -­‐ 0.238 M00805 LEF1 PLN 1394 Downstream
chr6:118862600..118862607 + 0.248 M01718 NFAT2 PLN -­‐6841 Upstream
chr6:118868178..118868196 -­‐ 0.258 M00152 SRF PLN -­‐1245 Upstream
chr6:118872338..118872344 + 0.26 M00805 LEF1 PLN 2897 Downstream
chr6:118869217..118869224 + 0.266 M01718 NFAT2 PLN -­‐224 Upstream
chr6:118873151..118873158 -­‐ 0.266 M01718 NFAT2 PLN 3717 Downstream
chr6:118866222..118866228 -­‐ 0.274 M00805 LEF1 PLN -­‐3213 Upstream
chr6:118868180..118868194 + 0.291 M00186 SRF PLN -­‐1261 Upstream
chr6:118872178..118872184 + 0.293 M00805 LEF1 PLN 2737 Downstream
chr6:118871192..118871198 + 0.306 M00805 LEF1 PLN 1751 Downstream
chr6:118872446..118872452 -­‐ 0.307 M00805 LEF1 PLN 3011 Downstream
chr6:118869414..118869441 -­‐ 0.31 M00957 PR PLN 0 Upstream
chr6:118862393..118862399 -­‐ 0.311 M00805 LEF1 PLN -­‐7042 Upstream
chr6:118863046..118863052 + 0.321 M00805 LEF1 PLN -­‐6395 Upstream
chr6:118872458..118872467 -­‐ 0.331 M00630 FOXM1 PLN 3026 Downstream
chr6:118866255..118866261 + 0.341 M00805 LEF1 PLN -­‐3186 Upstream
chr6:118861589..118861595 + 0.35 M00805 LEF1 PLN -­‐7852 Upstream
chr6:118872587..118872594 -­‐ 0.351 M01733 MZF1 PLN 3153 Downstream
chr6:118870078..118870085 + 0.357 M01665 IRF8 PLN 637 Downstream
chr6:118865891..118865898 + 0.357 M00240 Nkx2-­‐5 PLN -­‐3550 Upstream
chr6:118868178..118868197 -­‐ 0.359 M01007 SRF PLN -­‐1244 Upstream
chr6:118865261..118865267 + 0.361 M00805 LEF1 PLN -­‐4180 Upstream
chr6:118868177..118868196 + 0.366 M01007 SRF PLN -­‐1264 Upstream
chr6:118868177..118868192 -­‐ 0.371 M00922 SRF PLN -­‐1249 Upstream
chr6:118862113..118862120 + 0.374 M01665 IRF8 PLN -­‐7328 Upstream
chr6:118862836..118862842 + 0.374 M00805 LEF1 PLN -­‐6605 Upstream
chr6:118872588..118872594 -­‐ 0.398 MA0056 MZF1_1-­‐4 PLN 3153 Downstream
chr6:118862921..118862928 -­‐ 0.398 M00240 Nkx2-­‐5 PLN -­‐6513 Upstream
chr6:118871582..118871590 + 0.405 M00690 AP-­‐3 PLN 2141 Downstream
chr6:118871469..118871476 + 0.405 M01665 IRF8 PLN 2028 Downstream
chr6:118872481..118872488 + 0.47 MA0133 BRCA1 PLN 3040 Downstream
chr6:118869571..118869577 + 0.47 M01227 MAFB PLN 130 Downstream
chr6:118867379..118867386 -­‐ 0.475 M01733 MZF1 PLN -­‐2055 Upstream
chr6:118869814..118869821 + 0.484 M00747 IRF-­‐1 PLN 373 Downstream
chr6:118868109..118868115 + 0.492 M01227 MAFB PLN -­‐1332 Upstream
chr6:118865893..118865900 -­‐ 0.497 M00747 IRF-­‐1 PLN -­‐3541 Upstream
chr6:118865900..118865907 -­‐ 0.499 M00747 IRF-­‐1 PLN -­‐3534 Upstream
chr15:99639410..99639417 -­‐ 0 M00468 AP-­‐2rep SYNM -­‐5868 Upstream
chr15:99640307..99640313 -­‐ 0 M00704 TEF-­‐1 SYNM -­‐4972 Upstream
chr15:99640509..99640515 + 0 M00704 TEF-­‐1 SYNM -­‐4776 Upstream
chr15:99642703..99642709 -­‐ 0 M00704 TEF-­‐1 SYNM -­‐2576 Upstream
chr15:99643359..99643365 + 0 M00704 TEF-­‐1 SYNM -­‐1926 Upstream
chr15:99647195..99647201 + 0 M00704 TEF-­‐1 SYNM 1910 Downstream
chr15:99648597..99648603 -­‐ 0 M00704 TEF-­‐1 SYNM 3318 Downstream
chr15:99651624..99651630 + 0 M00704 TEF-­‐1 SYNM 6339 Downstream
chr15:99652306..99652312 -­‐ 0 M00704 TEF-­‐1 SYNM 7027 Downstream
chr15:99645142..99645161 + 0.003 MA0139 CTCF SYNM -­‐143 Upstream
chr15:99645189..99645205 -­‐ 0.008 M00287 NF-­‐Y SYNM -­‐80 Upstream
chr15:99643198..99643204 + 0.011 M01287 Neuro	  D SYNM -­‐2087 Upstream
chr15:99643198..99643204 -­‐ 0.011 M01287 Neuro	  D SYNM -­‐2081 Upstream
chr15:99647124..99647130 + 0.011 M01287 Neuro	  D SYNM 1839 Downstream
chr15:99647124..99647130 -­‐ 0.011 M01287 Neuro	  D SYNM 1845 Downstream
chr15:99645192..99645203 -­‐ 0.012 M00687 alpha-­‐CP1 SYNM -­‐82 Upstream
chr15:99638324..99638332 + 0.013 M00698 HEB SYNM -­‐6961 Upstream
chr15:99647123..99647130 -­‐ 0.014 M00644 LBP-­‐1 SYNM 1845 Downstream
chr15:99649137..99649143 + 0.014 M01287 Neuro	  D SYNM 3852 Downstream
chr15:99649137..99649143 -­‐ 0.014 M01287 Neuro	  D SYNM 3858 Downstream
chr15:99642941..99642947 + 0.015 M01287 Neuro	  D SYNM -­‐2344 Upstream
chr15:99642941..99642947 -­‐ 0.015 M01287 Neuro	  D SYNM -­‐2338 Upstream
chr15:99638612..99638618 -­‐ 0.016 M01287 Neuro	  D SYNM -­‐6667 Upstream
chr15:99638612..99638618 + 0.016 M01287 Neuro	  D SYNM -­‐6673 Upstream
chr15:99643198..99643205 + 0.017 M00644 LBP-­‐1 SYNM -­‐2087 Upstream
chr15:99638164..99638171 + 0.021 M01131 SOX10 SYNM -­‐7121 Upstream
chr15:99646460..99646466 + 0.021 M01287 Neuro	  D SYNM 1175 Downstream
chr15:99646460..99646466 -­‐ 0.021 M01287 Neuro	  D SYNM 1181 Downstream
chr15:99651752..99651758 + 0.021 M01287 Neuro	  D SYNM 6467 Downstream
chr15:99651752..99651758 -­‐ 0.021 M01287 Neuro	  D SYNM 6473 Downstream
chr15:99642940..99642947 -­‐ 0.024 M00644 LBP-­‐1 SYNM -­‐2338 Upstream
chr15:99642941..99642948 + 0.024 M00644 LBP-­‐1 SYNM -­‐2344 Upstream
chr15:99649614..99649621 -­‐ 0.024 M01709 MAFA SYNM 4336 Downstream
chr15:99649099..99649106 -­‐ 0.026 M01709 MAFA SYNM 3821 Downstream
chr15:99646459..99646466 -­‐ 0.03 M00644 LBP-­‐1 SYNM 1181 Downstream
chr15:99646460..99646467 + 0.03 M00644 LBP-­‐1 SYNM 1175 Downstream
chr15:99652618..99652624 + 0.035 M01287 Neuro	  D SYNM 7333 Downstream
chr15:99652618..99652624 -­‐ 0.035 M01287 Neuro	  D SYNM 7339 Downstream
chr15:99643629..99643636 + 0.039 M01131 SOX10 SYNM -­‐1656 Upstream
chr15:99638681..99638688 + 0.041 M01269 NURR1 SYNM -­‐6604 Upstream
chr15:99639948..99639955 -­‐ 0.044 M01131 SOX10 SYNM -­‐5330 Upstream
chr15:99652617..99652624 -­‐ 0.044 M00644 LBP-­‐1 SYNM 7339 Downstream
chr15:99643332..99643339 -­‐ 0.046 M01269 NURR1 SYNM -­‐1946 Upstream
chr15:99645016..99645023 -­‐ 0.049 M01269 NURR1 SYNM -­‐262 Upstream
chr15:99651357..99651364 + 0.05 M01207 ETS2 SYNM 6072 Downstream
chr15:99649359..99649365 -­‐ 0.052 MA0095 YY1 SYNM 4080 Downstream
chr15:99650986..99650993 -­‐ 0.055 M01268 FXR SYNM 5708 Downstream
chr15:99638638..99638644 + 0.058 MA0095 YY1 SYNM -­‐6647 Upstream
chr15:99648047..99648053 + 0.059 MA0095 YY1 SYNM 2762 Downstream
chr15:99647463..99647471 + 0.067 M00498 STAT4 SYNM 2178 Downstream
chr15:99642731..99642738 + 0.071 M01207 ETS2 SYNM -­‐2554 Upstream
chr15:99652606..99652614 -­‐ 0.071 M00498 STAT4 SYNM 7329 Downstream
chr15:99640259..99640266 -­‐ 0.074 M01207 ETS2 SYNM -­‐5019 Upstream
chr15:99646778..99646786 -­‐ 0.074 M00921 GR SYNM 1501 Downstream
chr15:99646227..99646233 -­‐ 0.075 MA0095 YY1 SYNM 948 Downstream
chr15:99640942..99640949 -­‐ 0.086 M01207 ETS2 SYNM -­‐4336 Upstream
chr15:99647028..99647036 -­‐ 0.097 M00494 STAT6 SYNM 1751 Downstream
chr15:99640483..99640491 + 0.1 M00497 STAT3 SYNM -­‐4802 Upstream
chr15:99646665..99646672 -­‐ 0.107 M00750 HMG	  IY SYNM 1387 Downstream
chr15:99646759..99646765 + 0.124 M01033 HNF4 SYNM 1474 Downstream
chr15:99647075..99647083 -­‐ 0.128 M00494 STAT6 SYNM 1798 Downstream
chr15:99651521..99651528 -­‐ 0.174 M00750 HMG	  IY SYNM 6243 Downstream
chr15:99642937..99642943 + 0.181 M01033 HNF4 SYNM -­‐2348 Upstream
chr15:99645193..99645206 -­‐ 0.181 M00775 NF-­‐Y SYNM -­‐79 Upstream
chr15:99643125..99643131 -­‐ 0.194 M01033 HNF4 SYNM -­‐2154 Upstream
chr15:99646286..99646292 + 0.195 M01033 HNF4 SYNM 1001 Downstream
chr15:99649403..99649409 -­‐ 0.195 M01033 HNF4 SYNM 4124 Downstream
chr15:99649210..99649216 -­‐ 0.201 M01033 HNF4 SYNM 3931 Downstream
chr15:99651374..99651381 -­‐ 0.202 M00799 Myc SYNM 6096 Downstream
chr15:99645191..99645205 + 0.223 M00209 NF-­‐Y SYNM -­‐94 Upstream
chr15:99640879..99640885 -­‐ 0.224 M01033 HNF4 SYNM -­‐4400 Upstream
chr15:99651222..99651228 -­‐ 0.225 M00805 LEF1 SYNM 5943 Downstream
chr15:99646290..99646298 + 0.257 M01240 BEN SYNM 1005 Downstream
chr15:99640884..99640892 + 0.268 M01240 BEN SYNM -­‐4401 Upstream
chr15:99638218..99638226 + 0.272 M00690 AP-­‐3 SYNM -­‐7067 Upstream
chr15:99638078..99638084 -­‐ 0.297 M00805 LEF1 SYNM -­‐7201 Upstream
chr15:99647465..99647472 + 0.303 M01718 NFAT2 SYNM 2180 Downstream
chr15:99643452..99643459 + 0.306 M01718 NFAT2 SYNM -­‐1833 Upstream
chr15:99651393..99651399 -­‐ 0.308 M01032 HNF4 SYNM 6114 Downstream
chr15:99645192..99645203 -­‐ 0.319 M00185 NF-­‐Y SYNM -­‐82 Upstream
chr15:99651775..99651782 + 0.323 M01718 NFAT2 SYNM 6490 Downstream
chr15:99643010..99643017 + 0.325 M01665 IRF8 SYNM -­‐2275 Upstream
chr15:99651411..99651418 + 0.334 M01658 AML1 SYNM 6126 Downstream
chr15:99651264..99651271 -­‐ 0.335 M01665 IRF8 SYNM 5986 Downstream
chr15:99643014..99643020 + 0.337 M00805 LEF1 SYNM -­‐2271 Upstream
chr15:99648000..99648006 + 0.343 M01032 HNF4 SYNM 2715 Downstream
chr15:99647719..99647725 -­‐ 0.346 M00805 LEF1 SYNM 2440 Downstream
chr15:99647954..99647960 -­‐ 0.349 M00805 LEF1 SYNM 2675 Downstream
chr15:99650987..99650993 -­‐ 0.361 M01032 HNF4 SYNM 5708 Downstream
chr15:99649480..99649487 -­‐ 0.364 M00240 Nkx2-­‐5 SYNM 4202 Downstream
chr15:99651019..99651026 -­‐ 0.365 M01665 IRF8 SYNM 5741 Downstream
chr15:99643179..99643185 + 0.368 M00805 LEF1 SYNM -­‐2106 Upstream
chr15:99647398..99647404 + 0.391 M00805 LEF1 SYNM 2113 Downstream
chr15:99646818..99646824 + 0.44 M01227 MAFB SYNM 1533 Downstream
chr15:99649531..99649538 -­‐ 0.442 M00240 Nkx2-­‐5 SYNM 4253 Downstream
chr15:99651241..99651247 + 0.467 M01227 MAFB SYNM 5956 Downstream
chr15:99638396..99638402 + 0.474 MA0056 MZF1_1-­‐4 SYNM -­‐6889 Upstream
chr15:99643172..99643179 + 0.477 M01733 MZF1 SYNM -­‐2113 Upstream
chr15:99653272..99653279 -­‐ 0.479 M01733 MZF1 SYNM 7994 Downstream
chr15:99646360..99646366 + 0.481 MA0056 MZF1_1-­‐4 SYNM 1075 Downstream
chr15:99648712..99648719 + 0.483 M01733 MZF1 SYNM 3427 Downstream
chr15:99640388..99640395 -­‐ 0.499 M01733 MZF1 SYNM -­‐4890 Upstream
chr4:119802949..119802955 + 0 M00704 TEF-­‐1 SYNPO2 -­‐7046 Upstream
chr4:119803010..119803016 -­‐ 0 M00704 TEF-­‐1 SYNPO2 -­‐6979 Upstream
chr4:119803653..119803659 -­‐ 0 M00704 TEF-­‐1 SYNPO2 -­‐6336 Upstream
chr4:119805740..119805750 + 0 M01211 PARP SYNPO2 -­‐4255 Upstream
chr4:119809198..119809209 -­‐ 0 M01596 GLI3 SYNPO2 -­‐786 Upstream
chr4:119810339..119810345 + 0 M00704 TEF-­‐1 SYNPO2 344 Downstream
chr4:119811424..119811443 -­‐ 0 LM2_CTCF CTCF SYNPO2 1448 Downstream
chr4:119813049..119813055 + 0 M00704 TEF-­‐1 SYNPO2 3054 Downstream
chr4:119813609..119813616 -­‐ 0 M00468 AP-­‐2rep SYNPO2 3621 Downstream
chr4:119815381..119815388 -­‐ 0 M00468 AP-­‐2rep SYNPO2 5393 Downstream
chr4:119810534..119810540 + 0.006 M01287 Neuro	  D SYNPO2 539 Downstream
chr4:119810534..119810540 -­‐ 0.006 M01287 Neuro	  D SYNPO2 545 Downstream
chr4:119809309..119809316 + 0.009 M01709 MAFA SYNPO2 -­‐686 Upstream
chr4:119810353..119810360 -­‐ 0.009 M01709 MAFA SYNPO2 365 Downstream
chr4:119809554..119809561 + 0.01 M01709 MAFA SYNPO2 -­‐441 Upstream
chr4:119809199..119809209 + 0.014 M01042 GLI1 SYNPO2 -­‐796 Upstream
chr4:119809198..119809210 -­‐ 0.016 M01037 GLI SYNPO2 -­‐785 Upstream
chr4:119810762..119810769 -­‐ 0.024 M01269 NURR1 SYNPO2 774 Downstream
chr4:119812729..119812736 -­‐ 0.025 M01269 NURR1 SYNPO2 2741 Downstream
chr4:119802981..119802987 -­‐ 0.03 MA0095 YY1 SYNPO2 -­‐7008 Upstream
chr4:119809199..119809208 -­‐ 0.037 M00449 Zic2 SYNPO2 -­‐787 Upstream
chr4:119804259..119804265 -­‐ 0.044 MA0095 YY1 SYNPO2 -­‐5730 Upstream
chr4:119814118..119814124 + 0.044 MA0095 YY1 SYNPO2 4123 Downstream
chr4:119804362..119804372 -­‐ 0.053 M01261 HNF3A SYNPO2 -­‐5623 Upstream
chr4:119804274..119804281 -­‐ 0.055 M01207 ETS2 SYNPO2 -­‐5714 Upstream
chr4:119817819..119817825 -­‐ 0.057 MA0095 YY1 SYNPO2 7830 Downstream
chr4:119804248..119804255 -­‐ 0.06 M01207 ETS2 SYNPO2 -­‐5740 Upstream
chr4:119813997..119814004 -­‐ 0.062 M01269 NURR1 SYNPO2 4009 Downstream
chr4:119803009..119803024 + 0.063 MA0137 STAT1 SYNPO2 -­‐6986 Upstream
chr4:119805605..119805613 -­‐ 0.079 M00498 STAT4 SYNPO2 -­‐4382 Upstream
chr4:119815830..119815838 -­‐ 0.086 M01308 SOX4 SYNPO2 5843 Downstream
chr4:119811418..119811432 -­‐ 0.087 MA0119 TLX1::NFIC SYNPO2 1437 Downstream
chr4:119811180..119811187 -­‐ 0.109 M00750 HMG	  IY SYNPO2 1192 Downstream
chr4:119815408..119815416 + 0.112 M00658 PU.1 SYNPO2 5413 Downstream
chr4:119803012..119803021 + 0.126 M00223 STATx SYNPO2 -­‐6983 Upstream
chr4:119809199..119809210 + 0.126 M01704 GLI3 SYNPO2 -­‐796 Upstream
chr4:119816017..119816025 + 0.127 M00658 PU.1 SYNPO2 6022 Downstream
chr4:119809199..119809210 + 0.143 M01702 GLI1 SYNPO2 -­‐796 Upstream
chr4:119811176..119811184 + 0.155 M01117 OTX SYNPO2 1181 Downstream
chr4:119803009..119803024 + 0.195 M00459 STAT5B	  (homodimer) SYNPO2 -­‐6986 Upstream
chr4:119817251..119817257 + 0.195 M01033 HNF4 SYNPO2 7256 Downstream
chr4:119803009..119803024 + 0.199 M00457 STAT5A	  (homodimer) SYNPO2 -­‐6986 Upstream
chr4:119808995..119809002 + 0.205 M00750 HMG	  IY SYNPO2 -­‐1000 Upstream
chr4:119802703..119802709 -­‐ 0.207 M01033 HNF4 SYNPO2 -­‐7286 Upstream
chr4:119809199..119809210 + 0.212 M01703 GLI2 SYNPO2 -­‐796 Upstream
chr4:119809868..119809875 -­‐ 0.215 M00799 Myc SYNPO2 -­‐120 Upstream
chr4:119811364..119811371 -­‐ 0.217 M01665 IRF8 SYNPO2 1376 Downstream
chr4:119811361..119811367 -­‐ 0.219 M00805 LEF1 SYNPO2 1372 Downstream
chr4:119807973..119807981 -­‐ 0.237 M00671 TCF-­‐4 SYNPO2 -­‐2014 Upstream
chr4:119803363..119803369 + 0.261 M00805 LEF1 SYNPO2 -­‐6632 Upstream
chr4:119817566..119817573 -­‐ 0.291 M01665 IRF8 SYNPO2 7578 Downstream
chr4:119812999..119813005 + 0.308 M00805 LEF1 SYNPO2 3004 Downstream
chr4:119814715..119814722 -­‐ 0.308 M01718 NFAT2 SYNPO2 4727 Downstream
chr4:119810799..119810815 + 0.314 M01317 HOXC13 SYNPO2 804 Downstream
chr4:119813728..119813734 -­‐ 0.315 M00805 LEF1 SYNPO2 3739 Downstream
chr4:119803810..119803817 -­‐ 0.321 M01665 IRF8 SYNPO2 -­‐6178 Upstream
chr4:119803370..119803378 + 0.324 M00690 AP-­‐3 SYNPO2 -­‐6625 Upstream
chr4:119807974..119807980 + 0.334 M00805 LEF1 SYNPO2 -­‐2021 Upstream
chr4:119804934..119804940 -­‐ 0.338 M00805 LEF1 SYNPO2 -­‐5055 Upstream
chr4:119813940..119813947 + 0.342 M01665 IRF8 SYNPO2 3945 Downstream
chr4:119804444..119804450 -­‐ 0.351 M00805 LEF1 SYNPO2 -­‐5545 Upstream
chr4:119813662..119813669 -­‐ 0.353 M01665 IRF8 SYNPO2 3674 Downstream
chr4:119803126..119803133 + 0.366 M00240 Nkx2-­‐5 SYNPO2 -­‐6869 Upstream
chr4:119813936..119813942 + 0.367 M00805 LEF1 SYNPO2 3941 Downstream
chr4:119815928..119815935 -­‐ 0.367 M01665 IRF8 SYNPO2 5940 Downstream
chr4:119816082..119816089 + 0.382 M01665 IRF8 SYNPO2 6087 Downstream
chr4:119810587..119810594 + 0.411 M01733 MZF1 SYNPO2 592 Downstream
chr4:119813754..119813761 + 0.417 M01733 MZF1 SYNPO2 3759 Downstream
chr4:119808047..119808054 -­‐ 0.432 M00240 Nkx2-­‐5 SYNPO2 -­‐1941 Upstream
chr4:119810709..119810715 + 0.434 MA0056 MZF1_1-­‐4 SYNPO2 714 Downstream
chr4:119804709..119804716 -­‐ 0.439 M00240 Nkx2-­‐5 SYNPO2 -­‐5279 Upstream
chr4:119812059..119812065 + 0.439 MA0056 MZF1_1-­‐4 SYNPO2 2064 Downstream
chr4:119810587..119810593 + 0.443 MA0056 MZF1_1-­‐4 SYNPO2 592 Downstream
chr4:119803189..119803197 -­‐ 0.444 M01117 OTX SYNPO2 -­‐6798 Upstream
chr4:119805587..119805595 -­‐ 0.455 M01117 OTX SYNPO2 -­‐4400 Upstream
chr4:119809840..119809846 + 0.458 M01660 GABP-­‐alpha SYNPO2 -­‐155 Upstream
chr4:119813754..119813760 + 0.458 MA0056 MZF1_1-­‐4 SYNPO2 3759 Downstream
chr4:119802759..119802766 + 0.462 M01733 MZF1 SYNPO2 -­‐7236 Upstream
chr4:119802998..119803005 -­‐ 0.472 M01243 MTF1 SYNPO2 -­‐6990 Upstream
chr4:119817274..119817280 -­‐ 0.477 M01227 MAFB SYNPO2 7285 Downstream
chr4:119804668..119804674 + 0.481 MA0056 MZF1_1-­‐4 SYNPO2 -­‐5327 Upstream
chr4:119812819..119812826 -­‐ 0.481 M00747 IRF-­‐1 SYNPO2 2831 Downstream
chr4:119802759..119802765 + 0.487 MA0056 MZF1_1-­‐4 SYNPO2 -­‐7236 Upstream
chr4:119815379..119815385 -­‐ 0.493 MA0056 MZF1_1-­‐4 SYNPO2 5390 Downstream
Supplementary	  Table	  VIII:	  Genetic	  analysis	  of	  candidate	  SMCs	  markers	  loci	  in	  association	  to	  carotid	  IMT	  phenotypes	  
(raw	  p-­‐values	  reported	  in	  Table;	  significance	  levels	  after	  Bonferroni	  correction	  and	  number	  of	  SNPs	  tested	  for	  each	  gene
	  are	  indicated	  in	  the	  headlines;	  only	  SNPs	  with	  significant	  results	  are	  reported)
PDLIM7	  (n=16	  SNPs	  tested, PLN	  (n=637	  SNPs	  tested,	   SYNPO2	  (n=24	  SNPs	  tested,	  
corrected	  significance	   corrected	  significance corrected	  significance	  
p=0.003125) 	  p=9.29368E-­‐05) p=0.00208)
CHR 5 5 6 6 4
SNP rs11746443 rs35716097 chr6:119185974 chr6:119186493 rs4833611
BP 176798306 176806636 119079281 119079800 120147460
A1 A T G A T
Max_CC BETA -­‐0.005052 -­‐0.008738 0.005459 -­‐0.009305 0.0002154
SE 0.002912 0.002868 0.002855 0.00362 0.002842
P 0.08288 0.002332 0.05598 0.01021 0.9396
Mean_CC BETA -­‐0.003273 -­‐0.005266 0.003644 -­‐0.0065 -­‐0.0005459
SE 0.001827 0.001799 0.001789 0.002268 0.001781
P 0.07328 0.003452 0.04171 0.004175 0.7592
Max_l_CC BETA -­‐0.00006758 -­‐0.003169 0.006954 -­‐0.01309 -­‐0.0009964
SE 0.002567 0.002529 0.00252 0.003189 0.002508
P 0.979 0.2104 0.005813 0.00004144 0.6912
Mean_l_CC BETA -­‐0.000216 -­‐0.003566 0.005076 -­‐0.008463 -­‐0.0006467
SE 0.001981 0.001952 0.00194 0.002457 0.001932
P 0.9132 0.06784 0.008933 0.0005792 0.7378
Max_IMT BETA 0.0003577 -­‐0.0006055 0.01328 -­‐0.01237 -­‐0.0002705
SE 0.004056 0.003998 0.003975 0.005045 0.00396
P 0.9297 0.8796 0.0008466 0.01428 0.9455
Mean_IMT BETA -­‐0.00008371 -­‐0.002227 0.007917 -­‐0.008392 -­‐0.001366
SE 0.002152 0.002121 0.002109 0.002677 0.002102
P 0.969 0.2939 0.0001769 0.001731 0.5158
pr3_Max_1_CC BETA 0.001717 0.0003846 -­‐0.002659 0.006886 -­‐0.007522
SE 0.001879 0.00185 0.002198 0.002806 0.00221
P 0.3608 0.8354 0.2264 0.01418 0.0006729
fastest BETA -­‐0.01818 -­‐0.01691 0.002048 -­‐0.008911 -­‐0.00563
progression SE 0.005457 0.005372 0.00533 0.006805 0.005364
P 0.0008743 0.001658 0.7009 0.1905 0.294
legend:	  
Chr:	  chromosome,	  A1:	  coded	  allele,	  P:	  p-­‐value	  for	  association	  with	  IMT	  phenotypes	  
Max_CC:	  maximum	  IMT	  of	  the	  common	  carotid	  in	  a	  segment	  excluding	  the	  first	  cm	  proximal	  to	  the	  bifurcation
Max_l_CC:	  Max	  IMT	  value	  of	  the	  first	  centimetre	  of	  the	  common	  carotid	  arteries	  closest	  to	  the	  bifurcation	  (left	  and	  right)	  
Mean_l_CC:	  	  Mean	  IMT	  value	  of	  the	  first	  centimetre	  of	  the	  common	  carotid	  arteries	  closest	  to	  the	  bifurcation	  (left	  and	  right)	  
Max_IMT:	  maximum	  IMT	  measure	  considering	  the	  whole	  carotid	  tree	  derived	  from	  the	  segment-­‐specific	  measurements
Mean_CC:	  average	  IMT	  of	  the	  common	  carotid	  in	  a	  segment	  excluding	  the	  first	  cm	  proximal	  to	  the	  bifurcation
Mean_IMT:	  average	  IMT	  composite	  value	  considering	  the	  whole	  carotid	  tree	  derived	  from	  the	  segment-­‐specific	  measurements
pr3_Max_1_CC:	  3	  point	  progression	  of	  the	  maximum	  IMT	  of	  the	  first	  centimeter	  of	  Common	  Carotid	  artery	  	  (the	  one	  close	  to	  the	  bifurcation)	  right	  and	  left	  
fastest	  progression:	  fastest	  IMTmax	  progression	  detected	  in	  the	  whole	  carotid	  tree	  regardless	  of	  location	  
Supplementary	  Table	  IX:	  Functional	  data	  from	  REGULOME/ENCODE	  databases	  for	  SNPs	  associated	  with	  carotid	  IMT	  phenotypes
	  from	  genetic	  analyses
TF-­‐transcription	  factor
GENE SNP RegulomeDB	  TF	  binding	  score TF	  binding	  and	  function Proxy RegulomeDB	  TF	  binding	  score	   TF	  binding	  and	  function Distance	  (bp) RSquared DPrime
PDLIM7 rs11746443 Likely	  to	  affect	  binding,	  top	  score HEY1,	  cardiovascular	  development rs4075958 Likely	  to	  affect	  binding,	  top	  score 	  ETS1,	  expression	  of	  cytokines,	  cell	  proliferation,	  differentiation,	  migration	   13794 0.927 0.963
PDLIM7 rs11746443 Likely	  to	  affect	  binding,	  top	  score HEY1,	  cardiovascular	  development rs10866705 low 2825 0.754 0.955
PDLIM7 rs35716097 Likely	  to	  affect	  binding,	  high	  score HNF4A,	  proliferation rs10866705 low 5505 0.857 1
SYNPO2 rs4833611 low rs12645079 low 47052 0.81 1
SYNPO2 rs4833611 low rs2102541 low 32081 0.766 0.912
SYNPO2 rs4833611 low rs7668423 low 30248 0.701 0.871
PLN rs7742814 low rs7765824 low 5363 1 1
PLN rs7742814 low rs17826675 low 31609 0.74 1
PLN rs67456868 low rs11153777 low 52374 0.797 0.942
PLN rs67456868 low rs11153778 low 79622 0.797 0.942
PLN rs67456868 low rs669978 low 226809 0.797 0.942
PLN rs67456868 low rs2295709 low 87174 0.749 0.889
GENE SNP Genomic	  location,	  nearby	  genes Functional	  consequence MAF
PDLIM7 rs11746443 RGS14 intronic	  variant 0.1773
PDLIM7 rs35716097 outside unknown 0.3425
SYNPO2 rs4833611 USP53 intronic	  variant 0.3734
PLN rs7742814 outside unnown 0.3133
PLN rs67456868 outside unknown 0.0923
Supplementary	  Table	  X:	  Functional	  data	  from	  HAPLOREG	  database	  for	  SNPs	  associated	  with	  carotid	  IMT	  phenotypes
Query	  SNP:	  rs11746443	  and	  variants	  with	  r2	  >=	  0.8
freq freq freq freq histone	  marks histone	  marks bound changed GWAS	  hits hits hits genes func	  annot location
chr pos	  (hg38) (r²) (D') LD variant AMR ASN EUR SiPhy Enhancer DNAse Motifs NHGRI/EBI GRASP	  QTL Selected	  eQTL GENCODE dbSNP
5 177355217 0.8 0.94 rs13153019 T C 0.07 0.25 0.17 0.26 BLD 6	  tissues AIRE,PU.1 17	  hits 2.6kb	  5'	  of	  RGS14
5 177357511 0.89 0.95 rs4075958 G A 0.08 0.26 0.17 0.27 7	  tissues 14	  tissues 8	  tissues MAX 1	  hit 10	  hits 26	  hits 325bp	  5'	  of	  RGS14
5 177365742 0.89 0.95 rs11741640 G A 0.05 0.26 0.17 0.27 SKIN,	  LIV 11	  tissues ESDR,BLD,LIV 6	  altered	  motifs 20	  hits RGS14 intronic
5 177370342 0.96 1 rs4074995 G A 0.09 0.25 0.17 0.28 SKIN,	  GI,	  MUS 18	  tissues BLD,PANC IRC900814,STAT,Sp100 1	  hit 2	  hits 24	  hits RGS14 intronic
5 177371305 1 1 rs11746443 G A 0.06 0.25 0.17 0.28 21	  tissues 5	  tissues 7	  tissues HEY1,POL2 5	  altered	  motifs 1	  hit 21	  hits RGS14 intronic
5 177373053 0.94 0.99 rs11748165 C T 0.11 0.26 0.17 0.28 BLD 11	  tissues BLD,BLD Hic1 22	  hits 451bp	  3'	  of	  RGS14
5 177373360 0.96 0.99 rs11748297 G A 0.1 0.26 0.17 0.28 BLD 8	  tissues DMRT5 21	  hits 758bp	  3'	  of	  RGS14
5 177379813 0.8 0.95 rs138255156 TTTCC T 0.04 0.24 0.17 0.25 BLD,	  LIV EWSR1-­‐FLI1,SP1 SLC34A1
Query	  SNP:	  rs35716097	  and	  variants	  with	  r2	  >=	  0.8
freq freq freq freq histone	  marks histone	  marks bound changed GWAS	  hits hits hits genes func	  annot
chr pos	  (hg38) (r²) (D') LD variant AMR ASN EUR SiPhy Enhancer DNAse Motifs NHGRI/EBI GRASP	  QTL Selected	  eQTL GENCODE dbSNP
5 177372991 0.84 0.99 rs10051765 T C 0.49 0.32 0.26 0.33 BLD E2A,Ik-­‐1,LUN-­‐1 30	  hits 389bp	  3'	  of	  RGS14
5 177379635 1 1 rs35716097 C T 0.4 0.3 0.27 0.3 LIV,	  BLD 10	  tissues 19	  tissues 18	  bound	  proteinsAIRE,Rhox11 28	  hits SLC34A1
Query	  SNP:	  rs4833611	  and	  variants	  with	  r2	  >=	  0.8
freq freq freq freq histone	  marks histone	  marks bound changed GWAS	  hits hits hits genes func	  annot location
chr pos	  (hg38) (r²) (D') LD variant AMR ASN EUR SiPhy Enhancer DNAse Motifs NHGRI/EBI GRASP	  QTL Selected	  eQTL GENCODE dbSNP
4 119213621 0.92 0.96 rs12648052 A C 0.42 0.43 0.25 0.33 23	  tissues BLD 6	  tissues Hsf,SRF,STAT 7	  hits USP53 intronic
4 119214039 0.97 0.99 rs4621411 A G 0.4 0.43 0.25 0.33 23	  tissues 4	  tissues CTCF 6	  altered	  motifs 7	  hits USP53 intronic
4 119214980 0.98 0.99 rs10033031 G A 0.42 0.43 0.25 0.32 4	  altered	  motifs 7	  hits USP53 intronic
4 119217669 0.98 0.99 rs1134065 A C,G,T 0.42 0.43 0.26 0.32 8	  tissues SKIN 7	  hits USP53 5'-­‐UTR
4 119218028 0.98 0.99 rs74629660 G C 0.4 0.43 0.26 0.32 8	  tissues Spz1 6	  hits USP53 intronic
4 119218998 0.98 0.99 rs144747687 T TGCATA0.41 0.42 0.26 0.32 SKIN STRM,	  SKIN,	  VAS 10	  altered	  motifs 1	  hit USP53 intronic
4 119219427 0.99 1 rs11943184 A G 0.4 0.43 0.26 0.32 BRN 10	  tissues Hoxb8,SRF,YY1 6	  hits USP53 intronic
4 119221468 0.99 1 rs55903149 A AG,AGA0.39 0.43 0.26 0.32 PLCNT 5	  hits USP53 intronic
4 119221647 0.99 0.99 rs35886000 G A 0.4 0.43 0.26 0.33 PLCNT,	  MUS SKIN,SKIN Foxd1,Foxo,GCNF 6	  hits USP53 intronic
4 119221984 0.99 1 rs56090560 A T 0.4 0.43 0.26 0.32 DBP,Hdx 6	  hits USP53 intronic
4 119222111 0.99 1 rs62326359 G A 0.4 0.43 0.26 0.32 5	  altered	  motifs 6	  hits USP53 intronic
4 119222703 0.99 1 rs62328360 G A 0.4 0.43 0.26 0.32 FAT MIZF,Smad 6	  hits USP53 intronic
4 119222882 0.96 1 rs200152715 A AT 0.39 0.42 0.26 0.32 FAT 24	  altered	  motifs 7	  hits USP53 intronic
4 119225485 0.99 1 rs12643221 G A 0.4 0.43 0.26 0.32 E2A,TBX5,ZEB1 6	  hits USP53 intronic
4 119226305 1 1 rs4833611 C T 0.42 0.43 0.26 0.33 FAT,	  SKIN THYM POL2 4	  altered	  motifs 8	  hits USP53 intronic
4 119227213 0.99 1 rs11946597 A C 0.39 0.43 0.26 0.32 LNG,	  FAT,	  SKIN 5	  altered	  motifs 8	  hits USP53 intronic
4 119227355 0.99 1 rs76546029 A G 0.39 0.43 0.27 0.32 4	  tissues 7	  altered	  motifs 6	  hits USP53 intronic
4 119228507 0.99 1 rs61015834 C G 0.42 0.43 0.26 0.32 FAT 7	  hits USP53 intronic
Query	  SNP:	  rs7742814	  and	  variants	  with	  r2	  >=	  0.8
freq freq freq freq histone	  marks histone	  marks bound changed GWAS	  hits hits hits genes func	  annot
chr pos	  (hg38) (r²) (D') LD variant AMR ASN EUR SiPhy Enhancer DNAse Motifs NHGRI/EBI GRASP	  QTL Selected	  eQTL GENCODE dbSNP
6 118757157 0.91 0.96 rs62424023 A G 0.39 0.33 0.24 0.33 BLD,	  THYM NRSF 5	  hits 47kb	  5'	  of	  CEP85L
6 118757161 0.95 1 rs62424024 G A 0.36 0.32 0.23 0.32 BLD,	  THYM Pbx-­‐1 6	  hits 47kb	  5'	  of	  CEP85L
6 118758118 1 1 rs7742814 A G 0.37 0.32 0.24 0.33 BLD 4	  tissues 7	  hits 48kb	  5'	  of	  CEP85L
6 118760311 0.96 1 rs7745728 T A 0.34 0.33 0.24 0.34 BLD Hoxd10,Pax-­‐4 7	  hits 50kb	  5'	  of	  CEP85L
6 118760407 0.96 1 rs9320667 A G 0.34 0.33 0.24 0.34 BLD Foxp1,Irx 7	  hits 50kb	  5'	  of	  CEP85L
6 118762772 1 1 rs7740511 A G 0.3 0.31 0.24 0.33 BLD Cdx2,Hoxb8 5	  hits 51kb	  3'	  of	  MCM9
6 118763481 1 1 rs7765824 T G 0.27 0.31 0.24 0.33 BLD BLD RBP-­‐Jkappa 6	  hits 50kb	  3'	  of	  MCM9
6 118764003 0.95 1 rs6909006 G C 0.3 0.31 0.24 0.32 BLD 7	  altered	  motifs 5	  hits 49kb	  3'	  of	  MCM9
Query	  SNP:	  rs67456868	  and	  variants	  with	  r2	  >=	  0.8
freq freq freq freq histone	  marks histone	  marks bound changed GWAS	  hits hits hits genes func	  annot
chr pos	  (hg38) (r²) (D') LD variant AMR ASN EUR SiPhy Enhancer DNAse Motifs NHGRI/EBI GRASP	  QTL Selected	  eQTL GENCODE dbSNP
6 118747670 0.8 -­‐0.92 rs10691836 T TAC 0.71 0.85 0.98 0.84 RREB-­‐1 1	  hit 38kb	  5'	  of	  CEP85L
6 118758637 1 1 rs67456868 G A 0.11 0.13 0.03 0.17 BLD BLD,	  BRN 2	  hits 49kb	  5'	  of	  CEP85L
6 118782616 0.94 0.97 rs12194135 T G 0.12 0.14 0.03 0.17 ESDR 3	  hits 31kb	  3'	  of	  MCM9
6 118792308 0.9 0.97 rs12194458 C G 0.11 0.13 0.03 0.16 3	  hits 21kb	  3'	  of	  MCM9
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Materials and Methods 
 
Human material  
Patients undergoing surgery for symptomatic (S) or asymptomatic (AS), high-
grade (>50% NASCET) 1 carotid stenosis at the Department of Vascular 
Surgery, Karolinska University Hospital, Stockholm, Sweden were 
consecutively enrolled in the study and clinical data recorded on admission. 
Symptoms of plaque instability were defined as transitory ischemic attack 
(TIA), minor stroke (MS) and amaurosis fugax (AF). Patients without 
qualifying symptoms within 6 months prior to surgery were cathegorized as 
AS and indication for carotid endarterectomy (CEA) based on results from the 
Asymptomatic Carotid Surgery Trial (ACST) 2. Carotid endarterectomies 
(carotid plaques, CP) and blood samples were collected at surgery and 
retained within the Biobank of Karolinska Endarterectomies (BiKE). The BiKE 
study cohort demographics, details of sample collection, processing and 
analyses were as previously described 3. The microarray dataset is available 
from Gene Expression Omnibus (GSE21545). For immunohistochemistry 
additional tissues were used: normal radial arteries obtained at coronary by-
pass surgery, one internal carotid artery from a 61-year-old male treated for a 
neck tumor, and in-stent stenosis (intimal hyperplasia) tissue obtained from a 
patient after treatment of a traumatic aortic transection with a stent graft.  
The SOKRATES study comprises progressive aortic atherosclerotic lesions 
collected during organ transplantation, covering all age groups and the whole 
spectrum of atherosclerotic disease. Briefly, two centimetres of excessive 
aorta proximal and distal from the ostium of the renal artery was removed and 
lesions were classified according to adapted American Heart Association 
(AHA) classification 4 as proposed by Virmani et al 5.  Details of sample 
collection, demographics of the cohort along with tissue processing and full 
histological classification have been described previously 6. 
The database of IMPROVE, a large, multicenter, European longitudinal cohort 
study IMPROVE (acronym: Carotid Intima Media Thickness (IMT) and IMT-
PRogression as Predictors of Vascular Events in a High-Risk European 
Population) was used for studying single nucleotide polymorphism (SNP) 
associations with various cIMT measures. IMPROVE was set up for the study 
of cIMT measures as predictors of incident coronary events, and enrolled 
n=3711 subjects with at least three independent CAD risk factors. Detailed 
descriptions of IMPROVE, including the protocols for carotid ultrasound 
measures and SNP genotyping on Illumina CardioMetabochip and 
Immunochip arrays, have been reported 7-9. In the present study, a total of 
n=3378 subjects were available for the genetic association analyses. All 
samples were collected with informed consent from patients, organ donors or 
their guardians. All human studies were approved by the regional Ethical 
Committees. 
Antibodies 
The following primary antibodies obtained from Human Protein Atlas (HPA) 
were used: anti-Lmod1 (HPA030097), Synpo2 (HPA030665), Pdlim7 
(HPA048815), Pln (HPA026900). Anti-Synm antibody was purchased from 
Proteintech (20735-1-AP). For stainings of rat samples additional antibodies 
were purchased: anti-Pln (ab85146, Abcam) and Synpo2 (ab50192, Abcam).   
Quantitative PCR (qPCR) 
For quantitative PCR, total RNA was reverse-transcribed using High Capacity 
RNA-to-cDNA kit (4387406, Applied Biosystems, Life Technologies 
Corporation, Carlsbad, CA). PCR amplification was done in 96-well plates in 
7900 HT real-time PCR system (Applied Biosystems), using TaqMan® 
Universal PCR Master Mix (Applied Biosystems) and TaqMan® Gene 
Expression Assays (LMOD1 Rn01483340_m1, SYNM Rn00711100_m1, 
SYNPO2 Rn04244800_m1, PDLIM7 Rn01441766_m1, PLN Rn01434045_m1; 
MYOCD Rn01786178_m1, ACTA2 Rn01759928_g1, MYH11 
Rn01530317_m1; Applied Biosystems). All samples were measured in 
triplicates. Results were normalized to the equal mass of total RNA as well as 
the Ct values of RPLPO housekeeping control (Hs99999902_m1). The 
relative amount of target gene mRNA was calculated by 2-ΔΔCt method and 
presented as fold change. 
In situ RNA detection  
All reagents for in situ RNA detection were from Advanced Cell Diagnostics 
(ACDbio, USA). RNA detection was performed using RNAscope 2.0 HD 
Detection Kit Brown (#310033) on fresh frozen paraffin embedded tissues 
sectioned to 5 um thickness. Briefly, slides were heated to 57°C, 
deparaffinised, pretreated and probe hybridisation performed according to 
manufacturers instructions. All incubations were done in the HybEZ 
hybridisation oven. Probes targeting RNA of interest were the following: 
ACTA2 (311811), CNN1 (444131), PLN (444181), SYNPO2 (444161), 
LMOD1 (444141), PDLIM7 (444171), SYNM (444191), MYH11 (444151).  
Immunohistochemistry (IHC) 
All IHC reagents were from Biocare Medical (Concord, CA). Tissues were 
fixed for 24-48 hours in 2% Zn-formaldehyde at room temperature and 
paraffin-embedded. Isotype rabbit and mouse IgG were used as negative 
controls. In brief, 5 μm sections were deparaffinized in Tissue Clear and 
rehydrated in graded ethanol. For antigen retrieval, slides were subjected to 
high-pressure boiling in DIVA buffer (pH 6.0). After blocking with Background 
Sniper, primary antibodies were diluted in Da Vinci Green solution, applied on 
slides and incubated at room temperature for 1 hour. For colocalizations, 
antibodies for SMC-specific markers were used: anti-Myosin heavy chain 11 
(MYH11, sc65735, Santa Cruz), Calponin (ab700, Abcam), Smooth muscle α-
actin (SMA, M0851, DAKO). A double-stain probe-polymer system containing 
alkaline phosphatase and horseradish peroxidase was applied, with 
subsequent detection using Warp Red and Vina Green. Slides were 
counterstained with Hematoxylin QS (Vector Laboratories, Burlingame, CA), 
dehydrated and mounted in Pertex (Histolab, Gothenburg, Sweden). Images 
were taken using an automated ScanScope slidescanner or a Nikon 
OPTIPHOT-2 microscope equipped with a digital camera and processed with 
NIS-Elements software. Magnifications are indicated in figure legends. 
Immunofluorescence (IFL) 
Cells grown on glass coverslips were fixed in 4% paraformaldehyde for 10 
minutes at room temperature, permeabilized with 0.1 % Triton X-100/PBS for 
5 min, followed by blocking with 5% normal goat serum/PBS for 1 hour. Cells 
were then incubated with primary antibodies diluted in the blocking solution for 
1 hour at room temperature, washed with PBS and counterstained with Alexa 
Fluor 488 or 568-conjugated secondary antibodies (Invitrogen). Nuclei were 
stained with diamidino-2-phenylindole (DAPI) and fibrous-actin with 
Rhodamine-conjugated phalloidin. Images were taken in a multitrack mode, 
one channel at a time, using the Zeiss LSM510 confocal laser scanning 
microscope system and 100 oil immersion objective.  
Flow cytometry 
Cells were fixed with 4% paraformaldehyde and permeabilised with 0.1% 
Triton X-100/PBS for 5 min. Unspecific binding was blocked by incubation 
with 0.1% BSA/PBS and cell were stained with primary (SMA, M0851, DAKO) 
and secondary antibodies (Alexa 488, Invitrogen) diluted in 0.1% BSA/PBS for 
1h at room temperature. Analysis was performed on the CyAn flow cytometer 
(Beckman Coulter) and data processed using the FlowJo software.  
Primary rat aortic SMCs culture  
For isolation of primary rat SMCs (rSMCs), whole aortas were harvested, as 
previously described 10. Adventitia was removed and vessels were cut into 1 
mm pieces and digested in 0.1% collagenase in Ham's medium F-12 
of L- penicilin-streptomycin (medium F-12/0.1% 
BSA) for 10h. Cells were seeded (50 000 cells/cm2) on fibronectin-coated 
Petri dishes and cultured for 7 days either in medium F-12/0.1% BSA (serum-
free condition) or in medium F-12/0.1% BSA with 30ng/ml platelet derived 
growth factor BB (PDGFBB) 11. Cells were harvested for experiments after 1, 
3, 5 and days 7 of culture. Intact artery tissue was also used as reference 
when measuring expression levels of genes of interest. All cell culture 
experiments were repeated three times and representative images are shown.  
Primary human carotid artery SMCs culture and silencing of PDLIM7  
Low passage (3-4) primary human carotid artery artery SMCs (3014-05a, Cell 
Applications), were grown in 5% CO2 humidified environment at 37°C, in 
complete medium (311-500, Cell Applications). For siRNA transfections, 
growth medium was replaced with Opti-MEM (Gibco, Thermo Fisher Scientific) 
medium supplemented with 0.2% fetal bovine serum (FBS, Gibco). Cells were 
transiently transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s recommendations, separately with 2 siPDLIM7 (s194996 and 
s194997, Applied Biosystems) and mismatch (scrambled, 4390843, Applied 
Biosystems) control oligonucleotides diluted in Opti-MEM and applied at 200 
pmol/well for a 6-well plate. After 48 hrs of silencing, downregulation of 
PDLIM7 protein was evaluated by Western blot and immunofluorescence, and 
PDLIM7 siRNA s194997 was used in further experiments (Supplementary 
Figure X).  
Cell culture assays 
Human carotid SMCs were plated on fibronectin (PHE0023, Invitrogen) 
coated 6-well plates and left to adhere. After overnight serum-starvation, cells 
were treated with 20 ng/ml IFNγ (285-IF-100, R&D Systems) and collected at 
several time-points (2h, 4h, 8h and 24h) for RNA isolation and qPCR analyses.  
Cell proliferation was assessed using the colorimetric immunoassay based on 
the BrdU incorporation during DNA synthesis (11647229001, Roche), 
according to manufacturer protocol. Cell adhesion was assessed on 
fibronectin-coated 96-well plates, using a colorimetric assay according to 
standard protocol12. Briefly, cells were fixed with 4% paraformaldehyde, 
stained with 0.1% (w/v) Crystal Violet, 200 mM MES, pH 6.0 and thereafter 
treated with 10% (v/v) acetic acid. Cell spreading was quantified after 2 hours 
of plating, by measuring cell area using ImageJ software.  
Lipid-loading assays we performed in human aortic SMCs following the 
previously published protocol 13. Briefly, cells were incubated with oxLDL 
(XXX μg/ml, Company???) in 0.2% (w/v) BSA for 48 and 72 h. Cells 
incubated with 0.2% BSA without oxLDL treatment at corresponding time-
points, served as controls. All cell culture experiments were repeated three 
times, samples were measured in triplicates and representative results shown. 
Western blots 
Cells were treated with RIPA buffer on ice for extraction of proteins. Samples 
were reduced with β-mercaptoethanol and heated to 95ºC for 10 minutes. 
Proteins were separated using Mini-Protean® TGX™ Precast Gels 4-20% 
(BIORAD, California, USA) and transferred to Immun-Blot® PVDF membrane 
(BIORAD) for 1h. Blocking was done with 5% bovine serum albumin 
(BSA)/milk in 1xTTBS to minimize unspecific signal. Primary antibodies were 
added to the membranes in recommended dilutions and incubated in +4C ON. 
After washing in 1xTTBS the fluorescent IRDye800CW or IRDye680RD 
(Odyssey) secondary antibodies were incubated for 1h at RT. The 
membranes were analyzed in LICOR ODYSSEY scanner. 
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RNA-sequencing 
Human carotid artery SMCs were cultured in serum-free or 10% serum-
supplemented media for 48 hours (n=3 per condition) and total RNA was 
purified from 5x105 cells using the Qiagen miRNeasy kit. RNA libraries were 
prepared with the Illumina TruSeq library kit as described by the manufacturer 
and RNA sequenced using Illumina HiSeq 2500 (2x101). Reads contained in 
raw fastq files were mapped to hg19 using the RNA-seq aligner STAR 
(v2.4.0i). Mapped reads were counted using the htseq-count script distributed 
with the HTSeq Python package (https://pypi.python.org/pypi/HTSeq). 
Differential expression of exons, genes, and transcripts were assayed using 
the DESeq2 R package from Bioconductor 
(http://bioconductor.org/packages/release/bioc/html/DESeq2.html), which 
uses negative binomial distribution to estimate dispersion and model 
differential expression such as to permit biological variability to be different 
among tested genes (transcripts). 
ChIP-sequencing 
Human carotid artery SMCs were cultured in normal 5% serum-supplemented 
media for 48 hours and fixed in 1% formaldehyde to cross-link chromatin, 
followed by quenching with glycine. 2x107 cells were collected, and nuclear 
lysates were prepared as previously described 14. Chromatin nuclear lysates 
were then sheared to fragments of 100-500bp using a Bioruptor Pico 
sonicator (Diagenode) according to the manufacturer. 5ug H3K27ac antibody 
(Abcam) was added to sheared chromatin to immunoprecipitate protein-DNA 
complexes overnight at 4C. Following capture of the antibody-protein-DNA 
complexes to Protein G beads, the complexes were washed and eluted as 
previously described. Protein-DNA crosslinks were reversed and ChIP DNA 
was recovered using Qiagen PCR Purification kits. To generate the ChIP 
library, Illumina TruSeq adapters were ligated to the ChIP DNA, followed by 
PCR amplification and gel electrophoresis on a 2% agarose gel. ChIP DNA 
library fragments around 300bp were selected for PCR amplification. ChIP 
DNA library concentrations were quantitated by Qubit fluorometric and 
bioanalyzer analyses. Libraries were sequenced on an Illumina HiSeq 2500 
(2x101) to obtain approximately 45-50 million reads per barcoded sample. 
Resulting fastq files were aligned to human genome hg19 using bowtie2 to 
generate bam files and peaks were called using HOMER findPeaks with 
treatment sample as H3K27ac and control sample as IgG using the local 
filtering model, peak size of 1000, and an FDR threshold of 0.001. Fold 
change and p-value in H3K27ac vs. control were determined using a 
cumulative Poisson distribution. 
LC-MS/MS analysis and protein identification 
Atherosclerotic plaques from n=20 BiKE patients (n=10 symptomatic + 10 
asymptomatic; matched for male gender, age and statin medication) were 
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analysed using LC-MS/MS as previously described 15. Briefly, protein samples 
were iTRAQ labeled and pooled samples were separated on IPG strips. After 
separation, peptides were eluted into 72 fractions for each strip. These 
fractions were one by one subjected to reversed phase LC-MS/MS, where the 
peptides were fragmented to obtain the amino acid sequences. LC-MS was 
performed on a hybrid LTQ-Orbitrap Velos mass spectrometer (Thermo 
Fischer Scientific, San Jose, CA, USA). The fragment spectra from the mass 
spectrometer were matched to a database consisting of theoretical fragment 
spectra from all human proteins to obtain protein identities. Quantitative 
information was acquired by using the iTRAQ reporter ion intensities.  
Rat carotid artery balloon injury  
Carotid artery balloon injury was performed on male Sprague-Dawley rats, as 
previously described 16. The left carotid artery was dissected under isoflurane 
inhalation anesthesia, an arteriotomy performed in the external carotid artery 
and the common carotid artery de-endothelialized 3 times with a 2F Fogarty 
catheter. Animals were euthanized with isoflurane directly after injury (0h) or 
after 2h, 20h, 2 days, 5 days, 2 weeks, 6 weeks and 12 weeks after vascular 
injury and both the left (injured) and right (uninjured) common carotid arteries 
harvested (n=6 or 7 animals at each time point). Arteries were rinsed with 
PBS to remove blood. Eight additional animals were sacrificed and uninjured 
carotid arteries used as controls (intact). Arteries were divided in a proximal 
segment used for RNA isolation and a distal segment used for histology. Total 
RNA was used for microarray analysis with Affymetrix GeneTitan Rat Gene 
ST v1.1 arrays (part of a manuscript in preparation). Experiments were 
performed according to the protocols approved by the Regional Animal Ethic 
committee, Stockholm, and institutional guidelines for animal care were 
followed.  
Mouse model of atherosclerotic plaque vulnerability 
Analyses of gene expression were performed in an atherosclerotic carotid 
plaque rupture model in ApoE-deficient mice and contralateral control carotid 
arteries of the same mice 17, 18. The model in brief consists of an incomplete 
ligation (Vicryl 5-0 suture, Ethicon Endo-Surgery Inc, Blue Ash, USA) of the 
common right carotid artery (just below the bifurcation) for 4 weeks, which 
triggers intimal hyperplasia and non-ruptured carotid atherosclerotic lesions. 
To provoke rupture of the developed plaque, a conical polyethylene cuff is 
placed proximal to the ligation site for 4 days. Approximately 50% of the 16 
week old male mice display features of ruptured plaques, such as endothelial 
cracks or ulcers, and intraluminal thrombus formation. All experiments have 
been approved by the Stockholm Regional Board for Experimental Animal 
Ethics.   
Bioinformatic and statistical analyses  
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Gene expression and pathway analyses of the human plaque microarrays 
were previosly described in details 3. Pearson correlations were calculated to 
determine the association between mRNA expression levels from microarrays. 
Functional coupling network based on extended protein-protein interactions 
was constructed using FunCoup software (http://funcoup.sbc.su.se) and the 
one based on co-expression using GeneMania (www.genemania.org). 
Transcription factors binding motif analysis was performed using MotifMap 
(http://motifmap.ics.uci.edu) and MSigDB (Broad Institute) softwares, 
considering those with FDR<0.05. For genetic analyses, all SNPs in the 
region ±200 000 kb around the gene from the 1000 genomes pilot 1 CEU 
reference were tested that were present on the Illumina CardioMetabochip 
and Immunochip arrays. Linear regression analyses were performed between 
the SNPs and different cIMT measures using PLINK (v1.07) 19, assuming an 
additive genetic model and adjusting for age, gender and population 
stratification. All cIMT variables were logarithmically transformed before 
statistical analysis because of skewed distributions. Group comparisons were 
evaluated by the T-test, Mann-Whitney test or ANOVA when appropriate. In 
all analyses p-values were Bonferroni-corrected and p<0.05 after correction 
for multiple comparisons considered to indicate statistical significance. 
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